In *Crossing the Quality Chasm*, the Institute of Medicine defined six domains for improving the health care system. Health care should be safe, effective, patient-centered, timely, efficient, and equitable. Anesthesia professionals have long been acknowledged as leaders in patient safety, and they have worked to achieve the quadruple aim of promoting better patient outcomes, improving patient satisfaction, lowering clinician burnout, and lowering costs. While the safety of medicine and anesthesiology has significantly improved over the last century, we have not seen equivalent gains in equitable care, which is defined as care does not vary in quality based on personal characteristics such as gender, ethnicity, geographic location, or socioeconomic status.

The United States Centers for Disease Control and Prevention defines disparities as preventable differences in the burden of disease, injury, violence, or opportunities to achieve optimal health that are experienced by socially disadvantaged populations. A large share of negative health outcomes occurs within a small subset of our patient population. Far too often, whether it is infant or maternal mortality, cardiovascular disease and its complications, or unmanaged acute and chronic pain, this population subset disproportionately consists of people of diverse backgrounds. Furthermore, racial and ethnic disparities have been identified in anesthesiology.

Several studies have focused on the racial and ethnic differences in the management of pain for surgical procedures or during labor and delivery. Neuraxial labor analgesia is the most effective treatment modality in the management of labor pain. Both the American Congress of Obstetricians and Gynecologists and the American Society of Anesthesiologists promote the use of neuraxial analgesia due to its efficacy and safety, both for the mother and her neonate.

The APSF has recognized for many years that understanding how to use medical technology is fundamental to patient safety. In an effort to promote that understanding, APSF is pleased to announce a new educational program on the use of medical technology. APSF has partnered with the University of Florida Center for Safety, Simulation and Advanced Learning Technologies under the direction of Sem Lampotang, PhD, to develop a web-based educational program. This program will be available to all anesthesia professionals and requires only an internet connection and web browser to access the content. Continuing education credits are intended to be offered.

Two topics have been chosen for the initial educational offerings—Low-Flow Anesthesia and Quantitative Neuromuscular Transmission Monitoring. The recognition that inhaled anesthetic agents are greenhouse gases that contribute to global warming has created a growing interest in the practice of Low-Flow Anesthesia. While the technique can be safely and effectively practiced, there are patient safety implications. The goal of the Low-Flow education is to empower anesthesia professionals with the knowledge required to safely, effectively, and comfortably reduce fresh gas flow and the environmental impact of their practice. Neuromuscular blockade monitoring has long been considered essential to safe patient care when administering muscle relaxants.

To Our APSF Readers:
If you are not on our mailing list, please subscribe at https://www.apsf.org/subscribe and the APSF will send you an email of the current issue.
TABLE OF CONTENTS

ARTICLES:

Why a Focus On Diversity, Equity, and Inclusion is a Perioperative Patient Quality and Safety Imperative..........................Page 43
APSF Initiative on Medical Technology Education........................................Page 43
Patient Safety and Low-Flow Anesthesia.......................................................Page 54
Off-Label Low-Flow Sevoflurane: Regulatory Red-Herring or Liability Landmine?.................................Page 57
Anesthesia Pain and Safety Considerations in Cancer Patients..............................Page 59
Managing COVID-19 in the Perioperative Setting....................................................Page 62
A Patient’s Right to Refuse Medical Treatment..................................................Page 64
Patient Safety and Quantitative Neuromuscular Transmission Monitoring in 2022..........................Page 66
Perioperative Considerations of Cannabis Use on Anesthesia Administration........Page 67
Highlights from the ISMP Summit: The Future of Perioperative Medication Safety: Charting Our Path Forward..................Page 71

LETTERS TO THE EDITOR:

The Impact of Health Disparities in Patient Safety...............................................Page 73
Sustainable Health Care Must Be the Next Patient Safety Movement......................Page 75

APSF ANNOUNCEMENTS:

Guide for Authors.......................................................................................Page 44
APSF Stoelting Conference 2022: Crucial Patient Safety Issues in Office-Based and Non-Operating Room Anesthesia (NORA)........................Page 55
Crowdfunding.......................................................................................Page 58
Anesthesia Quality and Patient Safety Meeting 2022..................................Page 61
APSF Donor Page...............................................................................Page 70
APSF Newsletter Podcast Now Available Online @ APSF.org/podcast........Page 72
Get Social With Us!........................................................................Page 76
Legacy Members..................................................................................Page 77

2022 Board Members and Committee Members:..................................https://www.apsf.org/about-apsf/board-committees/

Guide for Authors

A more detailed Guide to Authors with specific requirements for submissions can be found online at https://www.apsf.org/authorguide

The APSF Newsletter is the official journal of the Anesthesia Patient Safety Foundation. It is widely distributed to a variety of anesthesia professionals, perioperative providers, key industry representatives, and risk managers. Therefore, we strongly encourage publication of those articles that emphasize and include the multidisciplinary, multiprofessional approach to patient safety. It is published three times a year (February, June, and October). Deadlines for each issue are as follows: 1) February Issue: November 15th, 2) June Issue: March 15th, 3) October Issue: July 15th. The content of the newsletter typically focuses on anesthesia-related perioperative patient safety. Decisions regarding content and acceptance of submissions for publication are the responsibility of the editors.

1. All submissions should be submitted via Editorial Manager on the APSF website: https://www.editorialmanager.com/apsf
2. Please include a title page, which includes the submission’s title, authors’ full name, affiliations, conflicts of interest statement for each author, and 3–5 keywords suitable for indexing. Please include word count on the title page (not including your work).
3. Please include a summary of your submissions (3–5 sentences), which can be used on the APSF website to publicize your work.
4. All submissions should be written in Microsoft Word in Times New Roman font, double-spaced, size 12.
5. Please include page numbers on the manuscript.
6. References should adhere to the American Medical Association citation style.
7. References should be included as superscript numbers within the manuscript text.
8. Please include in your title page if Endnote or another software tool for references is used in your submission.
9. Authors must submit written permission from the copyright owner to use direct quotations, tables, figures, or illustrations that have appeared elsewhere, along with complete details about the source. Any permission fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the APSF. Unpublished figures require permission from the author.

Types of articles include (1) review articles, Pro/Con Debates and Editorials, (2) Q and As, and (3) letters to the Editor, (4) Rapid Response, and (5) Conference reports.
1. Review articles, invited Pro/Con debates, and Editorials are original manuscripts. They should focus on patient safety issues and have appropriate referencing. The articles should be limited to 2,000 words with no more than 25 references. Figures and/or tables are strongly encouraged.
2. Q&A articles are submitted by readers regarding anesthesia patient safety questions to knowledgeable experts or designated consultants to provide a response. The articles should be limited to 750 words.
3. Letters to the editor are welcome and should be limited to 500 words. Please include references when appropriate.
4. Rapid Response (to questions from readers), formerly known as “Dear SIRS,” which is the “Safety Information Response System,” is a column that allows for expedient communication of technology-related safety concerns raised by our readers, with input and response from manufacturers and industry representatives. Jeffrey Feldman, MD, current chair of the Committee on Technology, oversees the column and coordinates the readers’ inquiries and the response from industry.

Commercial products are not advertised or endorsed by the APSF Newsletter; however, upon exclusive consideration from the editors, articles about certain novel and important safety-related technological advances may be published. The authors should have no commercial ties to, or financial interest in, the technology or commercial product.

If accepted for publication, copyright for the accepted article is transferred to the APSF. Permission to reproduce articles, figures, tables, or content from the APSF Newsletter must be obtained from the APSF.

Individuals and/or entities interested in submitting material for publication should contact the Editors (Steven Greenberg, MD, and Jennifer Banayan, MD) directly at greenberg@apsf.org or banayan@apsf.org.

Address all general, contributor, and subscription correspondence to:
Stacey Maxwell, Administrator Anesthesia Patient Safety Foundation P.O. Box 6668 Rochester, MN 55903, U.S.A. maxwell@apsf.org

Address Newsletter editorial comments, questions, letters, and suggestions to:
Steven B. Greenberg, MD Editor, APSF Newsletter greenberg@apsf.org Jennifer M. Banayan, MD Editor, APSF Newsletter banayan@apsf.org Edward A. Bittner, MD, PhD Associate Editor, APSF Newsletter bittner@apsf.org

Send contributions to:
Anesthesia Patient Safety Foundation P.O. Box 6668 Rochester, MN 55903, U.S.A. Or please donate online at www.apsf.org.
Racial and Ethnic Disparities Exist in the Rates of Neuraxial Anesthesia for Cesarean Delivery

From “Diversity,” Page 43

Yet, despite 60% of delivering women using neuraxial labor analgesia for pain control in the US,9 Black and Hispanic women are less likely to use neuraxial labor analgesia for pain control in labor when compared to non-Hispanic White women (62%, 48% and 69%, respectively).10-12 Among Hispanic women, there is an additional difference in the use of neuraxial labor analgesia based on primary spoken language, with primarily Spanish-speaking women being less likely to both anticipate (adjusted odds ratio 0.70 [97.5% CI: 0.53-0.92]) and use (adjusted odds ratio 0.88 [97.5% CI: 0.78-0.99]) neuraxial analgesia compared to English-speaking Hispanic women.13 These differences in neuraxial labor analgesia use may have safety implications at the time of cesarean delivery. Neuraxial anesthesia is the preferred mode of anesthesia for cesarean deliveries because of the multiple maternal and neonatal benefits of neuraxial anesthesia compared to general anesthesia.14-16 Yet, racial and ethnic disparities exist in the rates of neuraxial anesthesia for cesarean delivery,17 with the rate of general anesthesia use being almost double for black women compared to non-Hispanic White women (11.3% versus 5.2%).18 Little information exists about why this discrepancy exists (e.g., differences in risk factors for general anesthesia by race/ethnicity, etc.) as most studies on racial and ethnic discrepancies between modes of anesthesia for cesarean delivery have been population-level studies. These are a few examples of the many studies which have documented racial and ethnic disparities in health care.

Understanding the root causes of the disparities is fundamental to building effective interventions. Disparities can arise at the patient-, provider-, or health care system-level.17 At the patient-level, considerations such as health literacy, patient’s understanding of their medical condition and treatment choices, and primary spoken language can all contribute to disparities. At the provider level, knowledge of treatment options and provider bias may also contribute to disparities. At the health care systems level, there may be differences based on the hospitals’ resources.

Given the multiple levels from which disparities can arise, it is important to measure the differences by race/ethnicity, and track changes as interventions are implemented. The gold standard is to have patients self-identify their race and ethnicity. Other strategies, such as staff identification or use of patient surnames have been proven to be inaccurate.18,19 In one study, which compared hospital staff’s accuracy with identification of patient’s race and ethnicity, compared to patient self-reported race and ethnicity, which were collected for a different purpose, the range of agreement was imperfect for all racial and ethnic groups.18 The hospital staff could select race and ethnicity from six categories (Hispanic, American Indian, Black/African American, Asian, White, and unknown/missing). The agreement was best for White patients (76%), but decreased with the other racial and ethnic groups 68% for Black/African American, 57% for Hispanics, 33% for Asians, and 1% for American Indians.18 Ensuring accurate race/ethnicity and language data is critical for building dashboards to evaluate disparities in local care. While anesthesia professionals may not be directly collecting this information, it is imperative that they work with hospital leadership to ensure that this data is being accurately collected.

Clinicians should also be trained in the use of shared decision-making (SDM). Shared decision-making allows active discussion between patients and providers. In SDM, providers share relevant risks, benefits, and alternatives of treatments with the patient. In addition, the patient also shares personal information and beliefs that would make a treatment more or less desirable.20,21 Given that anesthesia professionals often do not have the luxury of pre-existing relationships with a patient, this may be a way to garner trust and understand any fears or mis-conceptions held by the patient. Some groups have long-standing historical distrust of the medical establishment. One of the most glaring examples underlying this distrust is the infamous Tuskegee Study, where Black men were denied treatment for syphilis and deceived by clinicians and the US government.22 Consequently many Black patients come into the medical system with trust deficit. Therefore an “equal” amount of time and level of engagement from a physician—especially one of a different racial background—may not engender an equivalent degree of trust in all patients. Strategies to enhance trust and communication between patients and their providers are important for achieving equity. Incorporating opportunities to build rapport and discuss treatment options with patients preoperatively, such as through a preoperative clinic, may be one way to begin to build trust and engage patients prior to the day of surgery.

Additional solutions to reduce disparities can be identified at the patient-, provider-, and health care systems-level. In addition to using shared decision-making, it is important that providers counsel patients in their preferred spoken language, and use professional interpreters for communication with patients of limited-English proficiency.23 Also, ensuring patient educational material is both readable, and meets patient’s health literacy needs, will improve patient-provider communication.24,25

See “Diversity,” Next Page
A Focus on Diversity, Equity, and Inclusion
Will Improve Patient Safety, Quality, and Outcome

From “Diversity,” Preceding Page

At the provider-level, raising awareness of disparities and creating a culture of equity can be achieved through education, departmental surveys, needs assessments, and creating forums for open dialogue. Furthermore, anesthesiology departments incorporate best practices for workforce diversity and engage in mentorship programs, such as the Doctors Back to School Program, that will help expose premedical students, as well as medical students to our field. In addition, the Diversity in Anesthesiology Program focuses on educating, empowering, and mentoring underserved populations with information to enhance a career in anesthesiology. This list is not comprehensive, but meant to illustrate several of the tangible ways that anesthesiology professionals can engage in reducing disparities.

Anesthesia professionals are leaders in improving patient safety by identifying problems and potential solutions, testing them, and scaling effective interventions. Our field has expanded its scope beyond the operating room into the preoperative and postoperative setting. Addressing disparities should be the next horizon for our specialty. Whether our patients have language barriers, or are differently abled, or come from communities who have long experienced discrimination within the health care systems, ample evidence exists that a focus on diversity, equity, and inclusion will improve patient safety, quality, and outcomes.

Paloma Toledo, MD, MPH, is an assistant professor at Northwestern University Department of Anesthesiology.

Jerome Adams, MD, MPH, is a professor at Purdue University Department of Anesthesiology and executive director of Purdue’s Health Equity Initiative.

The authors have no conflicts of interest.

REFERENCES

Technology Education

From “Technology Education,” Page 43

Technology for neuromuscular transmission monitoring continues to advance and this educational program will help the practitioner develop an understanding of the latest technologies and their potential to enhance the safe use of muscle relaxants.

APSF has engaged with several companies who manufacture technologies relevant to these educational topics. APSF does not, however, promote any particular device or manufacturer. The educational content will be device agnostic. APSF will allow links to educational content on company websites that are device specific. This should facilitate access for users to device specific knowledge.

APSF will not, however, have any responsibility for the content presented through those industry web links.

Look for the details of this exciting program in the October issue of the 2022 APSF Newsletter.

Jeffrey Feldman, MD, MSE is chair, APSF Committee on Technology and professor of clinical anesthesiology at Children’s Hospital of Philadelphia Perelman School of Medicine

Samson Lampotang, PhD, FSSH, FAIMBE, holds the JS Gravenstein Professorship of Anesthesiology and is director, CSSALT and Innovations Director, Office of Medical Education at the University of Florida College of Medicine.

Jeffrey Feldman, MD, is a consultant for Medtronic, Becton-Dickinson, and Micropore. Samson Lampotang, PhD, has no conflicts of interest.

REFERENCES
Anesthesia Patient Safety Foundation Update:
2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway
by John E. Fiadjoe, MD, and David Mercier, MD

The recently published 2022 ASA guidelines for managing the difficult airway are a significant change from previous guidelines. These changes are meant to assist clinicians in decision-making. As airway management equipment improves, human factor concerns, team-based performance, and cognitive errors remain hurdles to safe airway management. Change can be difficult and, in this article, the authors highlight some of the important changes to the guidelines.

Robert Glazer, founder and chairman of the Board of a global partner marketing agency, shares a blog every Friday called “Friday Forward,” which we highly recommend (https://www.robertglazer.com/fridayfwd/). In it, he described the four stages of change:
1. Confusion and surprise—“Huh? why did you change that?”
2. Reacting to differences—“Why is this different, not sure I like that.”
3. Pining for the past—“Oh, I wish I had the old version back, this sucks.”
4. Adaptation and acceptance—“Hmm, this may actually be better, I think I like it.”

Many of you may have had one of these reactions to the new ASA practice guidelines for managing the difficult airway. Regardless of which stage of change you’re in, this article will highlight changes to the guidelines and usher you closer to the final stage of change.

GUIDELINE HISTORY
The initial ASA Practice Guidelines for Management of the Difficult Airway were published in 1993. Since then, the ASA Committee on Standards and Practice Parameters (now the Committee on Practice Parameters) has been tasked with reviewing each guideline published by the various task forces every five years. Additionally, each guideline must undergo a complete revision at least every ten years. This version, published in January 2022, is the revision of the 2013 ASA Guidelines. This article summarizes the fundamental changes to the previous guidelines and emphasizes important considerations to enhance patient safety in airway management.

See “Difficult Airway Guidelines,” Next Page
Difficult airway infographic: Adult patient example. This figure provides three tools to aid in airway management for the patient with a planned, anticipated difficult, or unanticipated difficult airway. Part 1 is a decision tool that incorporates relevant elements of evaluation and is intended to assist in the decision to enter the awake airway management pathway or the airway management with the induction of anesthesia pathway of the ASA difficult airway algorithm. Part 2 is an awake intubation algorithm. Part 3 is a strategy for managing patients with induction of anesthesia when an unanticipated difficulty with ventilation (as determined by capnography) with a planned airway technique is encountered. a. The airway manager’s assessment and choice of techniques should be based on their previous experience; available resources, including equipment, availability, and competency of help; and the context in which airway management will occur. b. Review airway strategy: Consider anatomical/physiologic airway difficulty risk, aspiration risk, infection risk, other exposure risk, equipment and monitoring check, role assignment, and backup and rescue plans. Awake techniques include flexible intubation scope, videolaryngoscopy, direct laryngoscopy, supraglottic airway, combined devices, and retrograde wire-aided. c. Adequate ventilation by any means (e.g., face mask, supraglottic airway, tracheal intubation) should be confirmed by capnography, when possible. d. Follow-up care includes postextubation care (i.e., steroids, racemic epinephrine), counseling, documentation, team debriefing, and encouraging patient difficult airway registry. e. Postpone the case/intubation and return with appropriate resources (e.g., personnel, equipment, patient preparation, awake intubation). f. Invasive airways include surgical cricothyroidotomy, needle cricothyroidotomy with a pressure-regulated device, large-bore cannula cricothyroidotomy, or surgical tracheostomy. Elective invasive airways include the above, retrograde wire-guided intubation, and percutaneous tracheostomy. Other options include rigid bronchoscopy and ECMO. g. Invasive airway is performed by an individual trained in invasive airway techniques, whenever possible. h. In an unstable situation or when airway management is mandatory after a failed awake intubation, a switch to the airway management with the induction of anesthesia pathway may be entered with preparations for an emergency invasive airway. i. Low- or high-flow nasal cannula, head elevated position throughout procedure. Noninvasive ventilation during preoxygenation. j. The intent of limiting attempts at tracheal intubation and supraglottic airway insertion is to reduce the risk of bleeding, edema, and other types of trauma that may increase the difficulty of mask ventilation and/or subsequent attempts to secure a definitive airway. Persistent attempts at any airway intervention, including ineffective mask ventilation, may delay obtaining an emergency invasive airway. A reasonable approach may be to limit attempts with any technique class (i.e., face mask, supraglottic airway, tracheal tube) to three, with one additional attempt by a clinician with higher skills. k. Optimize: suction, relaxants, repositioning. Face mask: oral/nasal airway, two-hand mask grip. Supraglottic airway: size, design, repositioning, first versus second generation. Tracheal tube: introducer, rigid stylet, hyperangulated videolaryngoscopy, blade size, external laryngeal manipulation. Consider other causes of inadequate ventilation (including but not limited to laryngospasm and bronchospsas). l. First versus second generation supraglottic airway with intubation capability for initial or rescue supraglottic airway. m. Videolaryngoscopy as an option for initial or rescue tracheal intubation.

Figure 1, Part 3: Difficult Airway Infographic for Adult Patients.
New Airway Guidelines Are the First to Include Both Adult and Pediatric Airway Management

From "Difficult Airway Guidelines," Preceding Page

Difficult Airway Infographic: Pediatric Patients

A. Time Out for identification of the airway management plan. A team-based approach with identification of the following is preferred: the primary airway manager and backup manager and role assignment, the primary equipment and the backup equipment, and the person(s) available to help. Contact an ECMO team/otolaryngologic surgeon if noninvasive airway management is likely to fail (e.g., congenital high airway obstruction, airway tumor, etc.). B. Color scheme. The colors represent the ability to oxygenate/ventilate: green, easy oxygenation/ventilation; yellow, difficult or marginal oxygenation/ventilation; and red, impossible oxygenation/ventilation. Reassess oxygenation/ventilation after each attempt and move to the appropriate box based on the results of the oxygenation/ventilation check.

C. Nonemergency pathway (oxygenation/ventilation adequate for an intubation known or anticipated to be challenging): deliver oxygen throughout airway management; attempt airway management with the technique/device most familiar to the primary airway manager; select from the following devices: supraglottic airway, videolaryngoscopy, flexible bronchoscopy, or a combination of these devices (e.g., flexible bronchoscopic intubation through the supraglottic airway); other techniques (e.g., lighted stylets or rigid stylets may be used at the discretion of the clinician); optimize and alternate devices as needed; reassess ventilation after each attempt; limit direct laryngoscopy attempts (e.g., one attempt) with consideration of standard blade videolaryngoscopy in lieu of direct laryngoscopy; limit total attempts (insertion of the intubating device until its removal) by the primary airway manager (e.g., three attempts) and one additional attempt by the secondary airway manager; after four attempts, consider emerging the patient and reversing anesthetic drugs if feasible. Clinicians may make further attempts if the risks and benefits to the patient favor continued attempts.

D. Marginal/emergency pathway (poor or no oxygenation/ventilation for an intubation known or anticipated to be challenging): treat functional (e.g., airway reflexes with drugs) and anatomical (mechanical) obstruction; attempt to improve ventilation with facemask, tracheal intubation, and supraglottic airway as appropriate; and if all options fail, consider emerging the patient or using advanced invasive techniques. E. Consider a team debrief after all difficult airway encounters: identify processes that worked well and opportunities for system improvement and provide emotional support to members of the team, particularly when there is patient morbidity or mortality.

Developed in collaboration with the Society for Pediatric Anesthesia and the Pediatric Difficult Intubation Collaborative: John E. Fiadjoe, MD; Thomas Engelhardt, MD, PhD, FRCA; Nicola Disma, MD; Narasimhan Jagannathan, MD, MBA; Britta S. von Ungern-Sternberg, MD, PhD, DEAA, FANZCA; and Pete G. Kovatsis, MD, FAAP.

From “Difficult Airway Guidelines,” Preceding Page

NEW INTERNATIONAL PERSPECTIVES

The guidelines were developed by a task force of 15 members, including anesthesiologists and methodologists representing the United States, India, Ireland, Italy, Switzerland, and several subspecialty organizations.

GUIDANCE FOR BOTH PEDIATRIC PATIENTS AND ADULTS

Traditionally, these guidelines have focused on adult airway management. However, anesthesiology professionals are increasingly managing children. These guidelines include evidence and expert opinion on pediatric difficult airway management, which is a significant change that makes the guidelines more comprehensive.

NEW TECHNOLOGY, LITERATURE, AND EXPERT OPINION EVIDENCE

This update summarizes evidence from reviewing thousands of abstracts pared down to 560 references. Additionally, this iteration surveyed expert consultants, ASA members, and ten participating organizations on topics where the scientific evidence was scant or equivocal. It also updates the equipment and technology available for standard and difficult airway management.

EMPHASIS ON OXYGEN DELIVERY AND CO₂ CONFIRMATION

This version emphasizes oxygen administration throughout difficult airway management and during extubation. Additionally, it emphasizes using capnography to confirm tracheal intubation as in previous versions.

SITUATIONAL AWARENESS OF ATTEMPTS, THE PASSAGE OF TIME, AND OXYGEN SATURATION

These updated guidelines emphasize the importance of paying attention to the elapsed time during airway management. Too often, a team can suffer from task fixation, leading to multiple attempts using a single approach and failure to consider alternatives. Additionally, awareness of the oxygen saturation can enable early intervention and decision-making and limit the number of attempts. This increased situational awareness may help clinicians progress steadily through their planned airway management and recognize the need for a surgical airway earlier. A team-centered approach is best, and one approach is to assign an observer not involved with direct airway management as the arbiter of task fixation.

PRE-INDUCTION DECISION CHART FOR AWAKE VS. ASLEEP AIRWAY MANAGEMENT

Previous guidelines have been valuable for planning and identifying potential obstacles in developing a difficult airway management strategy. They included questions that helped with decision-making regarding awake airway management. However, judgment errors (i.e., not performing awake intubation when indicated) have led to failed airway securement, according to several reviews. To further support decision-making, this update includes a decision tree to aid in determining when awake airway management is indicated (Figure 1, Part 1). This decision tree is an extension and evolution of a work product published in 2004 by a task force member and adapted for the 2022 ASA algorithm. Awake intubation of the adult patient should be considered when there is (1) difficult ventilation (face mask/supraglottic airway), (2) increased risk of aspiration, (3) intolerance of brief apnea, or (4) expected difficulty with emergency invasive airway access.

Additionally, the new figures directly address the unanticipated difficult airway by including entry points after failed intubation after routine induction.

NEW ALGORITHMS AND INFOGRAPHICS FOR ADULT AND PEDIATRIC DIFFICULT AIRWAY MANAGEMENT

Tremendous time and effort were spent improving the new infographic’s flow and “real-time” usability. The new algorithm now includes a section that includes options involved in deciding to proceed with an awake airway (Figure 1, Part 2) as well as a section that is more amenable to “real-time” use (Figure 1, Part 3). The graphical design flows more like a cognitive aid than an algorithm, but requires review and familiarity before real-time use.

Both infographics are color-coded to represent the ability to ventilate. Green represents easy ventilation, yellow marginal, and red impossible ventilation. A time-out should occur before the start of airway management to discuss the care plan.

The team should identify the primary airway manager, the backup airway manager, the equipment to be used, and the person available to help if feasible. Both infographics highlight the importance of assessing ventilation after each attempt or intervention; the results of this assessment may move the clinician to a different point in the algorithm.

The pediatric algorithm highlights three main tools for managing a child with a difficult airway: the supraglottic airway (SGA), flexible intubation scope (FIS), and video laryngoscopy (VL) (Figure 2). These devices can be combined (e.g., FIS + SGA or FIS + VL) if they fail individually. These tools are most applicable to use in the easy ventilation zone; however, when ventilation is difficult, the clinician should focus on their best attempts to reestablish ventilation using a facemask, supraglottic airway device, and adjuncts, as well as their best attempt to perform tracheal intubation with the technique most likely to be successful. Both infographics highlight the importance of limiting attempts. The pediatric algorithm highlights the importance of distinguishing between functional and anatomical obstruction as their treatments differ. Drugs are required for functional obstruction and devices such as oropharyngeal, nasopharyngeal, and supraglottic airway devices for anatomic obstruction. A team debrief should be considered after airway management to codify lessons learned, allow team members to express any difficult emotions, and identify gaps for improvement.

PEDIATRIC HIGHLIGHTS

The early consideration of extracorporeal membrane oxygenation (ECMO) is highlighted in pediatric airway management. Airway management after inhaled induction is typical, while awake intubation is not commonly performed in children. The guidelines emphasize the importance of maintaining an adequate depth of anesthesia with ventilation assessment after every intubation attempt. The minimum number of attempts should be performed. Other rescue techniques to consider include rigid bronchoscopy by a clinician familiar with the method. Airway exchange catheters should be used with caution in children and used by clinicians experienced with their use. There is a small margin for error, and potential severe outcomes such as pneumothorax and pneumomediastinum may occur if the catheter perforates the airway.

DEVICES AND TECHNOLOGY

Meta-analyses of randomized trials have demonstrated that video-assisted laryngoscopy in patients with predicted difficult airways improves laryngeal views and first-attempt intubation success compared to direct laryngoscopy. These results were equivocal when comparing video-assisted laryngoscopy to flexible intubation scopes. Interestingly, randomized studies were also equivocal for the same outcomes when...
ASA Difficult Airway Algorithm for Adult Patients

**Pre-Intubation:** Before attempting intubation, choose between either an awake or post-induction airway strategy. Choice of strategy and technique should be made by the clinician managing the airway.¹

- Suspected difficult laryngoscopy? YES
  - Suspected difficult ventilation with face mask/supraglottic airway? YES
    - Significant increased risk of aspiration? NO
    - Increased risk of rapid desaturation? NO
  - Suspected difficult emergency invasive airway
    - Always evaluate for emergency invasive airway

  **Proceed with intubation attempt**

**Awake Intubation³**

- Awake intubation³
  - Mask ventilation adequate as confirmed by CO₂
    - Ventilation adequate/intubation unsuccessful
      - Consider alternative intubation approaches,⁷
        - invasive access⁴ or the feasibility of other options⁹
    - SUCCESS
  - MASK VENTILATION NOT ADEQUATE
    - CONSIDER/ATTEMPT SUPRAGLOTTIC AIRWAY⁶
      - SUPRAGLOTTIC AIRWAY VENTILATION ADEQUATE
        - EMERGENCY PATHWAY
          - LIMIT ATTEMPTS AND BE AWARE OF THE PASSAGE OF TIME. CALL FOR HELP/FOR INVASIVE ACCESS
            - Attempt alternative intubation approaches,⁷ as you prepare for emergency invasive airway⁵
              - FAIL
            - SUCCESS
      - SUPRAGLOTTIC AIRWAY NOT ADEQUATE
        - FAIL or deteriorating ventilation
          - Emergency invasive airway⁵
            - FAIL
            - SUCCESS
  - FAIL
  - Consider other options⁴
  - Postpone the case

**Airway electively secured by invasive access⁵**

**NON-EMERGENCY PATHWAY**

- Consider alternative intubation approaches,⁷ invasive access⁴ or the feasibility of other options⁹
  - SUCCESS
  - FAIL or deteriorating ventilation

**LIMIT ATTEMPTS AND CONSIDER AWAKENING³ THE PATIENT**

1. The airway manager’s choice of airway strategy and techniques should be based on their previous experience; available resources, including equipment, availability and competency of help; and the context in which airway management will occur.
2. Low- or high-flow nasal cannula, head elevated position throughout procedure. Noninvasive ventilation during preoxygenation.
3. Awake intubation techniques include flexible bronchoscope, videolaryngoscopy, direct laryngoscopy, combined techniques, and retrograde wire-guided intubation. Other options include, but are not limited to, alternative awake technique, awake elective invasive airway, alternative anesthetic techniques, induction of anesthesia (if unstable or cannot be postponed) with preparations for emergency invasive airway, and postponing the case without attempting the above options.
4. Invasive airway techniques include surgical cricothyrotomy, needle cricothyrotomy with a pressure-regulated device, large-bore cannula cricothyrotomy, or surgical tracheostomy. Elective invasive airway techniques include the above and retrograde airway techniques.
5. Consideration of size, design, positioning, and first versus second generation supraglottic airways may improve the ability to ventilate.
6. Alternative difficult intubation approaches include but are not limited to video-assisted laryngoscopy, alternative laryngoscope blades, combined techniques, intubating supraglottic airway (with or without flexible bronchoscopic guidance), flexible bronchoscopy, introducer, and lighted stylet or lightwand. Adjuncts that may be employed during intubation attempts include tracheal tube introducers, rigid stylers, intubating stylers, or tube changers and external laryngeal manipulation.
7. Includes postponing the case or postponing the intubation and returning with appropriate resources (e.g., personnel, equipment, patient preparation, awake intubation).
8. Other options include, but are not limited to, proceeding with procedure using face mask or supraglottic airway ventilation. Pursuit of these options usually implies that ventilation will not be problematic.
ASA Difficult Airway Algorithm for Pediatric Patients

Pre-Intubation: Before attempting intubation, choose between either an awake or post-induction airway strategy. Choice of strategy and technique should be made by the clinician managing the airway.

Suspected difficult laryngoscopy?

YES

Suspected difficult ventilation with face mask/supraglottic airway?

NO

INTUBATION ATTEMPT AFTER INDUCTION OF GENERAL ANESTHESIA

FAIL

SUCCESS

FAIL

SUCCESS

CONSIDER AWAKE/SEDATED APPROACH

Transfer to Tertiary Center if feasible

Awake Intubation

Airway electively secured by invasive access

FAIL

SUCCESS

FAIL or deteriorating ventilation

CONSIDER OTHER OPTIONS

Exclude/treat anatomical and functional obstruction

CONSIDER CALLING FOR INVASIVE ACCESS OR ECMO

MARGINAL

IMPOSSIBLE

MARGINAL

IMPOSSIBLE

EMERGENCY PATHWAY

CANNOT INTUBATE, CANNOT VENTILATE

CALL FOR HELP/FOR INVASIVE ACCESS

FAIL

SUCCESS

NON-EMERGENCY PATHWAY

CONSIDER EMERGING THE PATIENT

LIMIT ATTEMPTS

BE AWARE OF PASSAGE OF TIME

(REASSESS VENTILATION AFTER EACH ATTEMPT)

ADECUTE AS CONFIRMED BY CO₂

MARGINAL

IMPOSSIBLE

ADJUNCTS THAT MAY BE EMPLOYED DURING INTUBATION ATTEMPTS INCLUDE TRACHEAL TUBE INTRODUCERS, RIGID STYLETS, OR TUBE CHANGERS AND EXTERNAL LARYNGEAL MANIPULATION. B. OTHER OPTIONS INCLUDE, BUT ARE NOT LIMITED TO, PROCEEDING WITH PROCEDURE UTILIZING FACE MASK OR SUPRAGLOTTIC AIRWAY VENTILATION. PURSUIT OF THESE OPTIONS USUALLY IMPLIES THAT VENTILATION WILL NOT BE PROBLEMATIC.

Developed in collaboration with the Society for Pediatric Anesthesia and the Pediatric Difficult Intubation Collaborative: John E. Fiadjoe, MD; Thomas Engelhardt, MD, PhD, FRCA; Nicola Dima, MD; Narasimhan Jagannathan, MD, MBA; Britta S. von Ungern-Sternberg, MD, P.D, DEAA, FANZCA; and Pete G. Kovatsis, MD, FAAP.

Figure 4. ASA Difficult Airway Algorithm: Pediatric Patients.
Difficult Airway Guidelines (Cont’d)

From “Difficult Airway Guidelines,” Preceding Page

hyperangulated video laryngoscopes were compared to non-angled video laryngoscopes in anticipated difficult airway patients. Combination techniques may improve intubation success in patients with anticipated difficult airways. For example, using a flexible intubation scope through a supraglottic airway had a higher first-attempt success rate than using the flexible intubation scope alone.

**EXTUBATION AND DOCUMENTATION**

The guidelines highlight the importance of having an extubation strategy and preparing for reintubation if necessary. Consideration should be given to the personnel, the extubation location, and the equipment available. After extubation of difficult airway patients, clinicians should consider using an airway exchange catheter or laryngeal mask to allow rapid reintubation. The guidelines highlight the importance of communication and documentation. The clinical management must be communicated to the patient and documented in a letter. The patient should be encouraged to register with an emergency notification service. A detailed note should be added to the medical record.

**ASA HOUSE OF DELEGATES (HOD) APPROVAL**

The ASA HOD must approve all work products from the ASA Committee on Standards and Practice Parameters. A working draft of the guidelines was placed on the ASA website for all to review. All submitted comments were considered for inclusion. Interestingly, one of the common comments was that a portion of the ASA membership preferred the previous black and white algorithm style. Therefore, the algorithm was mainly kept in its original form with some minor modifications (Figure 3 and 4) after ASA HOD approval at the ASA annual meeting in October 2021.

**CONCLUSIONS**

These new guidelines are the first to include evidence from both adults and pediatric airway management. Although cloaked in the same garments (style, process and format) they radically depart from previous versions. They highlight the importance of risk assessment, provide a new decision tree to help determine when to consider awake airway management, awareness of task fixation and time passage, limiting the number of tracheal intubation attempts, and assessing ventilation after every intervention. Finally, they highlight the need to confirm intubation with capnography, plan for extubation, document the airway management in the medical record, and provide documentation to the patient. Welcome to the final stage of change.

**REFERENCES**


The benefits of low-flow anesthesia are well established and include reduced inhaled anesthetic waste, decreased cost, and fewer greenhouse gas effects. For the individual patient, low-flow anesthesia reduces loss of heat and humidity from the lungs. This article will highlight the common safety concerns of low-flow anesthesia. This is not intended to be a comprehensive guide to practicing low-flow anesthesia, which is well-described in the literature, and is a topic that will be covered in the upcoming APSF-ASA medical technology training initiative. The good news is that the risks of adopting low-flow anesthesia are readily managed, and patient safety concerns should not be a barrier to reducing fresh gas flow.

The “circle system” was designed to reduce anesthetic waste by allowing exhaled anesthetic agent to return to the patient in the inspired gases (Figure 1). Carbon dioxide (CO₂) absorption is fundamental to the design of the circle system. While CO₂ absorbents are necessary for safe use of the circle system, the presence of an absorbent does not guarantee the circle system is actually reducing waste. Effectively reducing waste requires the anesthesia professional to reduce fresh gas flow in a manner that allows exhaled gases to return to the patient.

Low-flow anesthesia is sometimes described as a total fresh gas flow of 1 liter/min. In practice however, low-flow anesthesia is not a single number. Depending upon the circumstances, 1 liter/min can be too much to achieve the desired degree of waste reduction, or too little to maintain an adequate concentration of oxygen or anesthetic in the circuit. For purposes of this discussion, the authors define the current practice of low-flow anesthesia as: Reducing fresh gas flow below minute ventilation to the lowest level consistent with equipment capabilities and provider comfort while ensuring safe and effective care for the patient. While reducing fresh gas flow unquestionably reduces waste, cost, and pollution, it is not without consequences that have implications for patient safety.

Effective oxygen delivery requires an inspired oxygen concentration that will maintain the desired concentration of oxygen in the blood. Anesthetic agent requirements are dictated by the need to maintain an adequate level of hypnosis and physiologic stability in the face of surgical stimulation and trauma. As fresh gas flow is reduced and rebreathing increases, the concentrations delivered in the fresh gas and the concentrations inspired by the patient can be quite different. Furthermore, gas and agent concentrations change in the circuit more slowly as fresh gas flow is reduced. Managing the relationship between delivered and inspired concentrations is the art and practice of low-flow anesthesia. It is important to note that control of carbon dioxide concentration is determined by minute ventilation and is unaffected by fresh gas flow.

**ENSURING ADEQUATE OXYGEN DELIVERY**

Concern for inadequate oxygen delivery leading to hypoxemia or inadvertent low inspired concentration of oxygen is reasonable as fresh gas flow is reduced. The concentration of oxygen in the exhaled gas (F̄ O₂) is always less than the inspired concentration (F̄₂ O₂) due to the patient’s oxygen consumption. As the percentage of rebreathed gas increases, F̄₂ O₂ mixes with the oxygen delivered to the patient in the fresh gas (F₂ O₂) to yield the F̄₂ O₂. The more exhaled gas is allowed to return to the patient, the greater the impact of F₂ O₂ on F̄₂ O₂ (Figure 1).

Continuous monitoring of inspired oxygen concentration is essential to the safe and effective practice of low-flow anesthesia. As flows are reduced, the practitioner estimates the delivered oxygen concentration (F̄₂ O₂) that will maintain the desired inspired concentration (F̄₂ O₂). Ultimately, the patient’s oxygen consumption and any leaks in the circuit will determine the F₂ O₂ delivered to the patient.

See “Low-Flow Anesthesia,” Next Page
Continuous Monitoring of Inspired and Expired Anesthetic Agent Concentration Is Essential to Safe Practice of Low-Flow Anesthesia

From “Low-Flow Anesthesia,” Preceding Page

Continuous FIO2 monitoring will help to guide adjustments to fresh gas flow. Since the FIO2 changes slowly at low fresh gas flow, a low oxygen concentration alarm can be set above the minimum safe level to provide a notification if FIO2 is heading lower than desired.

Managing inspired oxygen concentration during low-flow anesthesia is relatively straightforward since oxygen consumption is fairly constant during a procedure. Managing inspired anesthetic agent concentration is a bit more challenging since the uptake of agent falls exponentially over time.

ENSURING ADEQUATE INSPIRED ANESTHETIC AGENT CONCENTRATION

As mentioned previously, safe anesthetic agent delivery requires that the patient have a sufficient concentration to be unaware, but not so much that physiologic stability is threatened. Similar to the case of oxygen, the expired concentration of anesthetic agent (F_eAgent) will always be less than the inspired concentration of agent (FIAgent) due to uptake, except during emergence. Early in the procedure, when uptake of agent is high, the difference between F_eAgent and FIAgent can be substantial. For that reason, it is more difficult to reduce flows during induction and maintain the desired anesthetic concentration compared with the maintenance phase of the anesthetic when uptake has slowed and F_eAgent approaches FIAgent.

Continuous monitoring of inspired and expired anesthetic agent concentration is essential to the safe and effective practice of low-flow anesthesia. The difference between inspired and expired anesthetic agent concentration indicates the rate of uptake. As the difference narrows, uptake is slowing and it is easier to reduce flows and maintain the desired anesthetic concentration in the circuit. While the Delivered agent concentration, F_dAgent, is determined by the vaporizer setting, the FIAgent indicates what is being inspired by the patient. As flows are reduced, it may be necessary to increase the vaporizer setting above the MAC concentration in the patient to maintain the FIAgent and F_eAgent at the desired levels. Like oxygen delivery, setting the vaporizer is an estimate by the low-flow practitioner, and continuous agent concentration monitoring becomes essential to guiding vaporizer and fresh gas flow settings.

MANAGING FRESH GAS FLOW WHEN CHANGING OXYGEN AND AGENT CONCENTRATIONS

One major challenge to the practice of low-flow anesthesia is the rate of change of oxygen and agent concentrations in the circuit. The time constant for the rate of change is the internal volume of the anesthesia machine and breathing circuit in liters divided by the fresh gas flow in L/min. The internal volume can be 5 liters or more so that a fresh gas flow of 1 L/min could result in a time constant of 5 minutes, and it can take four-time constants to get close to equilibrium.

As fresh gas flow is reduced, concentrations of oxygen and anesthetic will change more slowly to reach a new equilibrium. As a result, the practitioner may change the gas mixture or vaporizer setting, but the ultimate impact on concentrations in the circuit will not be apparent for several minutes. This is another reason for continuous monitoring of oxygen and agent concentrations in the circuit as well as the use of high and low alarm limits to draw attention to slow changes that might otherwise go unnoticed. Indeed, it may be necessary to increase the total fresh gas flow to ensure that oxygen and agent concentrations change more quickly if needed.

DOES SEVOFLURANE HAVE A MINIMUM SAFE FRESH GAS FLOW?

The package insert for sevoflurane indicates that sevoflurane is safe when fresh gas flow is not less than 1 L/min for up to 2 MAC-Hours or not less than 2 L/min for longer procedures.5

See “Low-Flow Anesthesia,” Next Page
From “Low-Flow Anesthesia,” Preceding Page

This recommendation is neither scientifically sound nor consistent with a modern practice of low-flow anesthesia. Nevertheless, given the FDA labelling, practitioners may be understandably reluctant to reduce flows to less than these recommendations and deliver sevoflurane “off-label.” In another article on page 57 of this Newsletter, Brian Thomas JD, vice-president for Risk Management, Preferred Physicians Medical, provides some guidance on the actual medicolegal concerns associated with off-label medication administration. This article will briefly review the science that clearly indicates a lower flow limit for administration. This article will briefly review the practice of safe and effective low-flow anesthesia and the limitations of the circle system, set fresh gas flow and vaporizer concentrations to estimate patient needs, and continuously monitor the concentrations that result in the circuit. Interested in reducing the waste and pollution in your practice of inhaled anesthetics? Look for the APSF-ASA course on low-flow anesthesia to be available on the APSF website in the fall of 2022.

Jeffrey Feldman, MD, MSE, is chair, APSF Committee on Technology and professor of Clinical Anesthesiology at Children’s Hospital of Philadelphia. Lampotang has no conflicts of interest.

**Composition / Information on Ingredients**

### 2.2 Chemical Characterization (Preparation):

Soda lime containing calcium dihydroxide, calcium chloride, sodium hydroxide, 14–18% water and the indicator ethylviolet.

<table>
<thead>
<tr>
<th>CAS No.</th>
<th>Designation acc. to EC Directive</th>
<th>Content</th>
<th>Unit</th>
<th>Ident. Symbol</th>
<th>R-Phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>1305-62-0</td>
<td>Calcium dihydroxide / Calcium hydroxide (Ca(OH)₂) (EINECS-Nr. 215-137-3)</td>
<td>74–82 w/w per cent</td>
<td>X₁</td>
<td>R 41</td>
<td></td>
</tr>
<tr>
<td>10043-52-4</td>
<td>Calcium chloride</td>
<td>3–5 w/w per cent</td>
<td>X₂</td>
<td>R 36</td>
<td></td>
</tr>
<tr>
<td>1310-73-2</td>
<td>Sodium hydroxide</td>
<td>0.5–1 w/w per cent</td>
<td>C</td>
<td>R 35</td>
<td></td>
</tr>
<tr>
<td>2390-59-2</td>
<td>Ethyl Violet</td>
<td>&lt;0.1 w/w per cent</td>
<td>X₃</td>
<td>R 22–41</td>
<td></td>
</tr>
</tbody>
</table>

### 2.3 Additional Information:

Drägersorb® Free contents no ozone-depleting chemicals and no volatile organic chemicals (VOCs). During the manufacturing process for Drägersorb® Free no ozone-depleting chemicals and no volatile organic chemicals (VOCs) were used.

Abbreviations: CAS No = unique identifier for all compounds published by the Chemical Abstracts Service. Compound names are Designation according to European Commission Directive; W/W = Weight by weight expressed as a percentage e.g. 1% is 1 gram of the substance in 100g of the material; R-phrase = defined by the European Union Directive 67/548/EEC and describe special risks attributed to chemical preparations. (e.g., R-36 means irritating to the eyes)

**REFERENCES**


**CONCLUSION**

The practice of safe and effective low-flow anesthesia is an art that requires the practitioner to understand the capabilities and limitations of the circle system, set fresh gas flow and vaporizer concentrations to estimate patient needs, and continuously monitor the concentrations that result in the circuit. Interested in reducing the waste and pollution in your practice of inhaled anesthetics? Look for the APSF-ASA course on low-flow anesthesia to be available on the APSF website in the fall of 2022.

Jeffrey Feldman, MD, MSE, is chair, APSF Committee on Technology and professor of Clinical Anesthesiology at Children’s Hospital of Philadelphia Perelman School of Medicine.

Samsun Lampotang, PhD, FSSH, FAIMBE, holds the JS Gravenstein Professorship of Anesthesiology and is director, CSSALT and Innovations Centre Office of Medical Education at the University of Florida College of Medicine.

Dr. Feldman is a consultant for Medtronic, Becton-Dickinson, and Microprobe. Dr. Lampotang has no conflicts of interest.
Off-Label Low-Flow Sevoflurane: Regulatory Red Herring or Liability Landmine?

by Brian Thomas, JD

Administration of sevoflurane at low-flow rates remains a controversial practice due to the low-flow limits described in the Food and Drug Administration’s (FDA) required labeling. Specifically, the labeling in the United States requires no less than 1 L/min for up to 2 Minimum Alveolar Concentration (MAC)-Hours and no less than 2 L/min during longer exposures. While there is substantial evidence that Compound A is not toxic to humans and many carbon dioxide absorbents do not produce Compound A, the language in the labeling continues to influence practice. Labeling requirements create confusion about whether or not prescribing or administering a drug in an “off-label” manner (e.g., for a purpose not approved by the FDA) is safe and meets the standard of care. This article will address whether administering sevoflurane at off-label low-flow rates increases anesthesia professionals’ potential liability exposure in the event of an adverse outcome.

FDA APPROVAL AND OFF-LABEL USE

The FDA “plays a role in almost every aspect of the approval, marketing, labeling, advertising, and promotion of both over-the-counter and prescription drugs.” To approve a drug, the FDA must obtain sufficient information based on clinical testing to determine: 1) if the drug is safe and effective for the proposed use(s) and whether the benefits of the drug outweigh its risks; 2) whether the proposed labeling is appropriate and what (if anything) should be changed; and 3) whether the methods used in manufacturing the drug and the controls used to maintain its quality are adequate.

Once a drug is approved for a specific purpose, the drug can be used for any treatment even if the FDA did not approve that treatment. Using the drug for a purpose not indicated on its FDA-approved label is called an “off-label” practice. Off-label use is allowed by law in the context of therapy, but not allowed for research. The distinction between off-label use and research is important as the FDA closely regulates the development and clinical investigation (i.e., “research”) of new drugs. The FDA does not, however, regulate the practice of medicine, and anesthesia professionals are allowed to prescribe approved drugs for off-label use if such prescriptions do not qualify as “research.”

POTENTIAL MALPRACTICE LIABILITY

The most likely cause of action against an anesthesia professional who prescribes or administers a drug for an allegedly improper off-label use is the lack of informed consent.

INFORMED CONSENT

In the United States, the doctrine of informed consent generally requires an anesthesia professional to provide the patient or their legal surrogate with material information regarding the proposed treatment, the alternatives to treatment (including no treatment), the risks and potential benefits of the proposed treatment and alternatives. Given that information, the patient or their legal surrogate must be allowed to determine whether to consent to the proposed or alternative treatment. Most states apply the “reasonable anesthesia professional” standard when determining whether an adequate informed consent discussion was provided. This standard requires a determination by the jury or judge whether a reasonable anesthesia professional would have provided the material information necessary for the patient to make an informed decision.

In applying the doctrine of informed consent to off-label drug prescription or administration, many state courts have held that anesthesia professionals and other health care providers do not have to disclose to patients that a proposed use is off-label. For example, in one seminal appellate case, the court held:

“The decision whether or not to use a drug for an off-label purpose is a matter of medical judgment, not of regulatory approval. By analogy, the off-label use of a medical device is also a matter of medical judgment, and as such, subjects an [anesthesia professional] to professional liability for exercising professional medical judgment. Off-label use of a medical device is not a material risk inherently involved in a proposed therapy which an [anesthesia professional] should have disclosed to a patient prior to the therapy.”

Most states’ informed consent laws limit an anesthesia professional’s duty to providing medical information. In those states, the courts have held as a matter of law that there is no duty obligating an anesthesia professional to discuss the FDA regulatory status of drugs or products being used for a particular treatment, nor does a drug or product’s legal status (e.g., FDA-approved or off-label) affect the nature of the treatment.

However, a minority of states apply a “reasonable patient or person” standard of review for informed consent. That is, would a reasonable patient or person have considered the fact that a drug or medical device was going to be administered or used in an off-label manner material information for purposes of consenting to the treatment? Even in those states, the plaintiff would still need to prove that had the patient known the drug prescribed or administered was off-label, the patient would have refused the treatment.

Plaintiff attorneys continue to file lack of informed consent cases based on the fact that an anesthesia professional did not inform his or her client that the drug was administered in an unconstitutional manner.

See “Off-Label Sevoflurane,” Next Page
Anesthesia Professionals Are Allowed to Administer “Off Label” Drugs
If Such Drugs Do Not Qualify As “Research”

From “Off-Label Sevoflurane,” Preceding Page
off-label manner. A layperson on a jury could
give great deference to the fact the FDA did not
approve the use for which the anesthesia pro-
fessional prescribed or administered the drug,
even though such use may be widely
accepted.10 Additionally, plaintiff attorneys will
have little difficulty identifying anesthesiology
experts to testify that the administration of sevo-
flurane off-label for low-flow anesthesia is
below the standard of care based, at least in
part, on the manufacturer’s and FDA’s warning
label recommending against fresh flow rates < 1
L/min. However, if the anesthesia professional’s
care was appropriate, most of these cases are
defensible and do not result in settlement or
ever make it to trial.

CONCLUSION
Anesthesia professionals have safely pre-
scribed and administered a multitude of drugs
off-label for decades. A review of Preferred
Physicians Medical’s 4,594 anesthesia closed
claim files from 1987 to March 10, 2022, did not
identify any claims with allegations of patient
injury or death involving low-flow sevoflurane
anesthesia. The FDA does not regulate the
practice of medicine, and anesthesia profes-
sionals are allowed to prescribe and administer
drugs for off-label uses if such drugs do not
qualify as “research.” Like all medical judg-
ments, a decision to administer a drug “off-
lable” becomes a risk-benefit decision. While
the off-label use of a drug may potentially
increase the risk of liability, that risk may be miti-
gated by an adequate informed consent pro-
cess and adherence to the standard of care. In
summary, litigation involving allegations of neg-
ligence due to off-label administration of drugs
is uncommon and, in most cases, defensible on
behalf of anesthesia professionals.

Brian J. Thomas, JD, is vice president of Risk
Management at Preferred Physicians Medical
(PPM), a medical professional liability com-
pany for anesthesia professionals, in Over-
land Park, KS. Mr. Thomas is also a member of
the APSF Board of Directors and the APSF
editorial board.

The author has no conflicts of interest.

REFERENCES
accessdata.fda.gov/drugsatfda_docs/
2. Hendrickx J, Feldman J. There are no dragons: low-flow
anesthesia with sevoflurane is safe. Anesth Inten Care.
3. Zelany JL. The prescription drug user fee act: is a faster
Food and Drug Administration always a better Food and
4. Fritch DM. Speak no evil, hear no evil, harm the patient?
Why the FDA needs to seek more, rather than less, speech
from drug manufacturers on off-label drug treatments. Mich
5. Fox D. Safety, efficacy, and authenticity: the gap between
ethics and law in FDA decision making. Mich St L Rev.
2005;60:168.
6. Riley JB, Basilius PA. Physician’s liability for off-label pre-
Accessed April 12, 2022.
8. Beck JM, Azari ED. FDA, off-label use and informed con-
cent: debunking myths and misconceptions. Food Drug J.
9. Christopher WL. Off-label drug prescription: filling the regu-
10. Meadows WA, Hollowell BD. Off-label drug use: an FDA
regulatory term, not a negative implication of its medical

Join the #APSFCrowd!
Donate now at https://apsf.org/FUND

The Anesthesia Patient Safety Foundation is launching our first-ever crowdfunding
initiative, defined as raising small amounts of money from a large number of people.

Just $15 can go a long way to reach our goals.

Help support the vision that “no one shall be harmed by anesthesia care.”
Anesthesia Pain and Safety Considerations in Cancer Patients

by Dylan Irvine, BScH, and Jeffrey Huang, MD

INTRODUCTION:
The subspecialty of onco-anesthesia has gradually gained traction over the past few years. In addition to the comorbid diseases that some cancer patients present with, the interactions and consequences of their antineoplastic regimens must also be considered when devising an anesthetic plan. These new risks challenge the onco-anesthesia professionals with how to manage their patients safely. Preoperative considerations include the effect of chemotherapeutics on anesthesia administration. Intraoperative considerations include assessing the risks of intraoperative hypothermia in cancer patients, patient positioning and peripheral nerve injury considerations, and monitoring of an anesthetized patient. Postoperative considerations include managing the compound effects of postoperative pain with existing pain from a malignancy, as well as the associations between patient psychological support and postsurgical outcomes.

PREOPERATION CONSIDERATIONS
Effect of Chemotherapeutics on Anesthesia Administration—Cardiac and Pulmonary Considerations

The anesthesia professional must consider a specialized approach to anesthesia administration in patients undergoing chemotherapy treatment who require an elective or emergency surgery. Two of the most common systems affected by toxicities to chemotherapeutics include the cardiac and pulmonary systems, with the degree of toxicity depending on the specific agents employed, the dosage, and duration of use. Common chemotherapeutics associated with cardiac toxicity include busulfan, cisplatin, cyclophosphamide, doxorubicin, and 5-fluorouracil. For such patients, cardiac and respiratory function should be carefully evaluated prior to the anesthetic to identify the onset and etiology of potential complications. In an emergency situation, the use of Point of Care Ultrasound (PoCUS) can provide anesthesia professionals information regarding volume status, cardiac function, and respiratory function in patients who do not have adequate preoperative assessment.

Patients treated with anthracycline chemotherapy, a family of drugs extracted from Streptomyces spp., such as doxorubicin, may develop acute intraoperative left ventricular failure refractory to beta-adrenergic receptor agonists. This acute onset left ventricular failure is likely due to the risk of chemotherapy-induced cardiotoxicity associated with this drug class, which limits their use in some patients. In patients who develop chemotherapy-induced cardiotoxicity, the administration of phosphodiesterase inhibitors are indicated.

Common chemotherapeutics associated with pulmonary toxicity include methotrexate, bleomycin, busulfan, cyclophosphamide, cytarabine, and carbamustine. Patients can suffer pulmonary complications, such as dose-dependent interstitial pneumonitis and pulmonary veno-occlusive disease. Initial presentation may be limited to dry cough, breathlessness with exercise, and minimal changes on chest radiograph. However, postoperatively, these patients may require a period of mechanical ventilation. A high concentration of inspired oxygen has been shown to increase the risk of patients developing bleomycin-induced lung injury. Therefore, it has been recommended that reduced intraoperative and postoperative oxygen concentration should be used in patients being treated with bleomycin to reduce the risk of respiratory complications.

INTRAOPERATIVE CONSIDERATIONS
Intraoperative Hypothermia in Cancer Patients

Between 50%–70% of all surgical patients will experience intraoperative hypothermia. Surgical duration, age, and baseline body temperature have been identified as risk factors for developing intraoperative hypothermia. Cancer patients undergoing surgical treatment are often subject to increased surgical and anesthesia duration, and therefore may be at increased risk of developing intraoperative hypothermia (core body temperature < 36.0°C during surgery). Intraoperative hypothermia is associated with longer surgical recovery time for general anesthesia, arrhythmias, coagulopathies, longer duration of intubation, and increased postoperative length of hospitalization, compared to normothermic intraoperative patients. Hypothermia during cancer resection has been shown to have significant negative effects on postoperative immune function and cytokine levels, particularly in patients undergoing surgery for gastrointestinal cancer. Cancer patients with intraoperative hypothermia may suffer from an increased incidence of postoperative complications of any types, as well as a higher pathologic state and higher recurrence rate within 12 months, relative to normothermic patients.

Consequently, for anesthesia duration longer than 60 minutes, intraoperative warming should occur through convective heating using a forced-air warming blanket. Intraoperative infusions or transfusions should be warmed. Postoperatively, patients should be thermally insulated to prevent the development of
A Multimodal Analgesic Approach For Managing Cancer Patients' Pain is Preferred in the Perioperative Period

From “Cancer Patients,” Preceding Page

Hypothermia and medications such as clonidine or meperidine can be administered to control shivering.9 Dexmedetomidine displays similar efficacy to antishivering agents such as clonidine or meperidine, but may increase the risk of sedation, hypotension, dry mouth, and bradycardia.10

Intraoperative Patient Positioning and Peripheral Nerve Injury Prevention

In tumor resection surgeries, nerve injury can often occur because of compression and impingement on neural structures due to tumor tissue. Inappropriate patient positioning can lead to peripheral nerve injury as well. The ulnar nerve, brachial plexus, and common peroneal nerve are the most vulnerable to injury during surgery.11 Anesthesia professionals should be vigilant during the initial positioning and during the surgery. The use of padded arm boards or padding placed around the elbow has been shown to reduce the risk of upper extremity neuropathy perioperatively.12 Other padding can be strategically placed to limit the pressure of hard surfaces on the fibular head, which has been used to reduce the risk of peroneal neuropathy.12

Intraoperative Monitoring in an Anesthetized Cancer Patient

Intraoperative monitoring of high-risk patients (high-risk patients are defined by patient history, comorbidities, age, body mass index, ASA status, frailty, poor mobility, presence of terminal illness, and surgery type and complexity) may allow anesthesia professionals to detect the onset and etiology of shock states earlier so that targeted interventions can be implemented. In hemodynamically stable patients, continuous electrocardiographic monitoring, noninvasive blood pressure measurements, end tidal carbon dioxide monitoring, and peripheral pulse oximetry can be adequate intraoperatively.2 In hemodynamically unstable patients, an arterial line for continuous invasive blood pressure measurement and arterial blood gas analysis should be considered by anesthesia professionals.2 Implementation of PoCUS into clinical practice may provide additional information regarding volume status, cardiac function, lung status, and respiratory function, and is emerging as a fundamental approach for earlier detection of intra-abdominal or intrathoracic bleeding or fluid deficiency.2

POSTOPERATION CONSIDERATIONS: The Compound Effect of Postoperative Pain with Existing Pain Due to a Malignancy

The complexity of postoperative pain management for cancer patients is important for anesthesia professionals to consider. Barriers to adequate pain relief among cancer patients may be political (e.g., availability to opioids), prescriber-related (e.g., insufficient education around pain assessment and management, apprehension in prescribing opioids to patients, concerns relating to respiratory depression or excessive sedation), or patient-motivated (e.g., fear of addiction, fear that treatment implies final stages of life, fear of side effects).13 Pharmacologic management of mild cancer pain often involves nonopioid analgesia such as paracetamol/acetaminophen and/or non-steroidal anti-inflammatory drugs (NSAIDs). Treatment of moderate and severe cancer pain can involve the prescription of “weak,” or less potent opioids and “strong,” or more potent opioids, respectively.13 In postoperative cancer patients, pain management becomes more complicated due to the potential compounding effect from existing cancer pain, and the pain that can be manifested during the posturgical period. Persistent postsurgical severe pain has been witnessed in 5–10% of cancer patients, which is often the result of nerve injury followed by central sensitization in response to trauma.14

Many cancer patients have been on long-term and high-dose opioids; thus, their opioid requirements throughout the perioperative period will be increased.15 In these patients, multimodal analgesia strategies are important for providing a baseline of nonopioid analgesia, such as through the administration of paracetamol/NSAIDs and alpha-2-delta subunit modulators such as gabapentin.15 Perioperative intravenous ketamine reduces postoperative pain medication requirement and pain intensity.16 In a meta-analysis, it has been shown that the benefits of intraoperative lidocaine infusion to reduce pain are not yet confirmed.17

Alternatively, local anesthetic infusion with a long-term catheter placement has been shown to decrease the incidence of chronic pain postoperatively.18 Peripheral nerve blocks are also utilized for regional anesthesia postoperatively, and the complications, performance time, and local anesthetic requirements have been improved through the application of PoCUS.18 An advantage of peripheral nerve blocks in managing postoperative pain relative to central neuraxial blocks or general anesthesia is a reduction of systemic side effects such as sympathetic blockage and urinary retention.19 More recently, the emergence of fascial plane blocks has further expanded the applications of regional anesthesia in terms of managing postoperative pain for conditions involving the thorax and abdomen.19

Patient Psychological Considerations

Psychological distress, in particular, depression, in postoperative cancer patients is an emerging issue in the management of such patients. In these patients, referral and access to psychological support and counseling is important in improving patient outcomes. A study of cancer patients who underwent curative surgical resection for primary lung cancer demonstrates that depression and anxiety following surgery were aggravated by the presence of residual symptoms present following surgical intervention.20 In this study, thoracotomy, postoperative dyspnea, severe pain, and diabetes mellitus were identified as risk factors for postoperative depression, after controlling for the presence of preoperative depression.20
Challenges Faced By Onco-Anesthesia Professionals In Safely Managing Cancer Patients Are Complex

From “Cancer Patients,” Preceding Page

Providing access to psychological counseling is important at all stages of cancer treatment. Patients have shown benefit from psychological counseling at all stages of cancer care, from initial diagnosis to treatment and managing long-term functional effects. Psychological distress is also common in breast cancer patients who have undergone mastectomy. Compared to controls, the incidence of depression in patients who underwent mastectomy for breast cancer was significantly increased for up to three years following mastectomy, especially in younger adults. Overcoming and preventing postoperative depression in these patients through psychological counseling may improve morbidity and mortality in these patients.

CONCLUSION

The challenges faced by onco-anesthesia professionals in safely managing cancer patients perioperatively are diverse and complex. However, proper considerations of the potential risks between anesthesia administration and antineoplastic regimens must be taken to ensure the best quality of care while supporting these vulnerable patients.

Dylan Irvine is a second-year medical student at Nova Southeastern University College of Osteopathic Medicine, Davie, FL

Jeffrey Huang is a senior member of Anesthesiology, Health Outcomes and Behavior at Moffitt Cancer Center, and a professor of oncological science at the University of South Florida, FL

The authors have no conflicts of interest.

REFERENCES

Managing COVID-19 in the Perioperative Setting

by Jeremy Laney, MD, and Joseph W. Szokol, MD, FASA

For the past 2 years, the COVID-19 pandemic has bequeathed a plethora of barriers and unleashed its desolation on nearly every person on the planet. Infections have surpassed 445 million globally along with an excess of 5.9 million deaths;1,2 and these numbers continue to climb as the globalized vaccine efforts lag. Health care systems worldwide confronted unique challenges as hospital beds became saturated with infected patients during various surges throughout the pandemic. The challenge for health care systems to mitigate risks to patients while providing standard services remains, as immunization for SARS-CoV-2 continues to propagate and the in-hospital census of infected patients fluctuates.

Health care systems need to return to normalcy and provide surgical and procedural services safely, while mitigating the risk to SARS-CoV-2 positive patients. Determining the optimal timing of procedures for patients who have recovered from COVID-19 infection and the appropriate level of preoperative evaluation are challenging given the current lack of evidence or precedent for this disease. According to the Joint Statement Created by the APSF and ASA, “Elective surgeries should be performed for patients who have recovered from COVID-19 infection only when the anesthesia professional and surgeon or proceduralist agree jointly to proceed.”3 This should be done in conjunction with shared decision-making with the patient.

The most robust data analyzing perioperative outcomes of patients with SARS-CoV-2 infection emerged from the COVIDSurg Collaborative and GlobalSurg Collaborative study.4 This was an international, prospective, cohort study that included a total of 140,231 patients in 1,674 hospitals throughout 116 countries. They assessed the postoperative complications in patients with a diagnosis of SARS-CoV-2 infection with a primary outcome measure of 30-day postoperative mortality and a secondary outcome measure of 30-day postoperative complications (defined as pneumonia, acute respiratory distress syndrome, and unexpected postoperative ventilation). For patients with a SARS-CoV-2 diagnosis prior to surgical intervention, the mortality rates were as follows: 9.1% 0–2 weeks prior, 6.9% 3–4 weeks prior, 5.5% 5–6 weeks prior and 2.0% at ≥7 weeks (Figure 1). The mortality rates in the ≥7 weeks group demonstrated no significant difference when compared to the noninfected control group. Amongst the SARS-CoV-2 positive subjects, symptomatic patients demonstrated a significantly higher 30-day mortality rate across all time interval subgroups, when compared to those who were asymptomatic or had resolution of symptoms at the time of surgery. SARS-CoV-2 infected patients 0–2 weeks, 3–4 weeks, and 5–6 weeks prior to surgery demonstrated higher rates of postoperative pulmonary complications as well, and those with ongoing symptoms demonstrated the greatest risk. The ≥7 weeks subgroup complication rates mirrored that of the noninfected subjects.4

The beginning of the COVID-19 pandemic resulted in an overwhelming amount of admissions. Attempts to minimize in-hospital transmissions coupled with the lack of initial data on elective surgical risk for COVID-19 positive patients discussed in the previous section caused millions of cancellations and delays of elective surgeries worldwide. The National Institute for Health Research (NIHR) unit on Global Surgery collected data from 1,674 hospitals to address the perioperative risk of SARS-CoV-2 infected patients. This dataset delivers valuable information to providers responsible for mitigating risk to surgical candidates. Nonetheless, the large-scale study is not without its limitations. The diagnosis of a SARS-CoV-2 infection was not standardized and relies on the unique preoperative testing strategies of each institution, leaving the true time from infection-to-surgery in question.

Figure 1: Mortality rates of patients with SARS-CoV-2 diagnosis prior to undergoing surgery.
Managing COVID in the Perioperative Setting

From “COVID—Perioperative,” Preceding Page

Given the reliance on a single routine preoperative test, it is likely that a subgroup of subjects who recently recovered from a previous SARS-CoV-2 infection were misclassified as not infected. The pragmatic difficulties associated with conducting a cohort study of this scale rendered limitations in important subanalysis; assessing outcomes amongst groups controlling for type of surgery, type of anesthesia, airway device used, and chronic comorbidities would have been ideal with this dataset. The secondary outcomes measured in the study assessed the rates of pulmonary complications; however, it is well established that SARS-CoV-2 can cause an array of systemic complications including: thromboembolic events, myocarditis, overt stroke, cognitive deficiencies, and kidney injury.6 Lastly, data for this study were collected in October of 2020, prior to widespread vaccine distribution efforts and the emergence of a number of variants. As immunization propagates, through inoculation and infection, these outcomes will likely change.

Subsequent studies aimed at assessing similar findings have replicated the outcomes found in the COVIDSurg Collaborative study. Deng et al., recently published a retrospective study suggesting worse postoperative outcomes in those patients who had surgery within 8 weeks of SARS-CoV-2 diagnosis.6 In addition, the authors reported that a shorter time interval between diagnosis and intervention correlated with a higher rate of postoperative respiratory complications.6

The American Society of Anesthesiologists (ASA) and the American Patient Safety Foundation (APSF) released a joint statement in March of 2021 (recently updated in February 2022) with recommendations advising clinicians of the appropriate timing of elective surgeries in SARS-CoV-2 infected patients. Based on the accumulated data at that time, the statement issued the following recommended waiting times for infected patients:

- 4 weeks for asymptomatic patients or recovered from mild nonrespiratory symptoms
- 6 weeks for symptomatic patients who did not require hospitalization
- 8–10 weeks for a symptomatic patient who is diabetic, immunocompromised, or hospitalized
- 12 weeks for patients admitted to the Intensive Care Unit due to COVID-19 infection.3

These recommendations are not comprehensive and may not reflect patient demographics that providers will inevitably encounter. They are fluid recommendations that offer providers a framework to help estimate a risk/benefit ratio to decipher the appropriate timing of intervention patients need. The United Kingdom released similar guidelines, in February 2022, from a conglomerate of multidisciplinary perioperative specialists with analogous recommendations, discouraging operative intervention within 7 weeks of SARS-CoV-2 diagnosis.7

Although there is increasing information to address the timing of surgery after COVID-19 infection, the data and science unfortunately continues to lag behind the emerging variants, and data that supports the premise that vaccinated patients have a lower a risk of postoperative complications as compared to unvaccinated patients.8 According to the CDC, the Omicron variant causes less severe disease, and is more likely to reside in the oro- and nasopharynx without infiltration and damage to the lungs.9 Perioperative providers used these observations to prematurely conclude that the vaccinated patients recovering from Omicron should be at less risk for adverse events. However plausible, such a conclusion remains unproven. While there continues to be emerging data that can provide clinicians and patients with improved management strategies, health care providers will continue to require more data to fill in the knowledge gaps of the nuanced subanalyses.

Jeremy Laney, MD, is an assistant clinical professor in the Department of Anesthesiology, Cardiothoracic Division, Keck School of Medicine of USC.

Joseph W. Szokol, MD, FASA, is chief health policy officer of the American Society of Anesthesiologists and clinical professor in the Department of Anesthesiology at the Keck School of Medicine of USC. He is also the executive director of Mentorship and Physician Development in the Department of Anesthesiology at the Keck School of Medicine of USC.

The authors have no conflicts of interest.

REFERENCES

A Patient’s Right to Refuse Medical Treatment

by Brian Thomas, JD

The following information is a limited overview of competent adult patients’ right to refuse blood and blood products based on their religious beliefs. The right to refuse medical treatment is a very complex area of the law. It should be noted that this overview is not intended as legal advice. Statements of law and legal opinion should be carefully reviewed considering more recent statutory enactments and case law. Also, different standards may apply depending on the jurisdiction in which you practice.

INTRODUCTION

The right to refuse medical treatment is generally based on the common law right of self-determination of one’s body, the ethical principle of respect for autonomy, and the doctrine of informed consent. Further, the right to refuse treatment has also derived from a federal and state constitutional right to privacy. The United States Supreme Court has also held that a competent person has a liberty interest in the Due Process Clause in refusing any unwanted medical treatment. The right to refuse medical treatment may also be based upon the freedom of religion. Competent patients have the right to refuse any medical treatment, including blood and blood product transfusions, for themselves. Accordingly, a competent adult patient who does not want to receive blood or blood products should be required to sign a release that explains the risks inherent in refusing treatment and holds harmless any health care providers, hospital, facility, and any of their employees and agents from all liability arising out of the refusal of treatment. However, as the following case study highlights, even when competent adult patients or their legal representatives are provided with comprehensive informed consent discussions of the risks of refusing blood and blood products and those communications are documented in the medical record, that does not necessarily prevent litigation from being filed against those health care providers in the event of patient injury or death.

CASE STUDY

A 54-year-old male patient with a history of nausea, fatigue, and multiple syncopal episodes arrived via ambulance at the hospital emergency department. The patient was a Jehovah’s Witness and advised his providers he did not want to receive blood or blood products. His hemoglobin (Hgb) was 9.5.

After the patient was observed for approximately six hours, the clinical decision unit determined the patient should undergo esophagogastroduodenoscopy (EGD). While preparing for that procedure, the patient experienced hypotension and an increased heart rate upon attempting to stand. Because of this episode and his decreasing Hgb, an intensive care unit (ICU) consult was ordered.

The ICU staff evaluated the patient and noted that he was more hemodynamically stable while he was lying down. A progress note entered by the ICU attending indicated the gastroenterologist discussed the endoscopy with anesthesia but stated that “anesthesia determined the patient is currently too unstable to undergo the procedure at this time.” An ICU resident documented that he called the anesthesiologist and discussed the case, but the anesthesiologist was unwilling to take the patient for the endoscopy. The ICU staff then administered IV fluids in an effort to stabilize the patient for EGD, but his condition worsened over the next few hours.

An emergent EGD was ultimately performed bedside on the day of admission. The EGD revealed clotted blood in the gastric fundus and a bleeding ulcer in the intestine, which were coagulated by the endoscopist.

The following day the patient’s condition deteriorated, and he became more hemodynamically unstable: his Hgb dropped to 3.5, and he was intubated and sedated. An exploratory laparotomy was performed, and a 2-cm oozing ulcer was found on the medial wall of the duodenum. The ulcer was sutured and oversewn by the surgeon. Another anesthesiologist administered the general anesthetic for the second procedure. He noted that the patient’s power of attorney (POA) consented to the surgery and again refused blood products. The anesthesiologist noted in the preanesthesia evaluation that he informed the POA that without blood transfusion, the patient would probably not survive the surgery. The patient was assessed as an American Society of Anesthesiologists Physical Status 5E.

On the following day, the patient was administered 5 units of Hemopure®, a blood alternative, which increased his Hgb to 4.5. The patient survived the procedure and was returned to ICU. However, the patient went into cardiac arrest later that morning; resuscitation efforts were aborted following a discussion with the patient’s mother, and he expired.

The patient’s mother sued the emergency room physician, ICU resident, ICU physician, gastroenterologist, anesthesiologist, and the hospital. The plaintiff alleged the defendants breached the standard of care by failing to treat the patient’s internal bleeding in a timely manner.

See “Right-to-Refuse,” Next Page
Risk Management Strategies for Providers Who Provide Medical Care to Those Patients Who Refuse Medical Treatment

From “Right-to-Refuse,” Preceding Page

Plaintiff alleged the defendants should have performed the EGD and laparotomy sooner. Plaintiff retained three experts to support her theory: an internal medicine expert, a gastroenterology expert, and an anesthesiology expert. All three experts opined that the defendants breached the standard of care by failing to treat the patient before his blood count dropped so low.

The defendants moved for summary judgment disposition under state law. The defendants argued that, even if defendants were negligent, the doctrine of avoidable consequences precluded the plaintiff from recovering an award. Defendants noted that, under the doctrine of avoidable consequences, a party could not recover for losses that they could have avoided through reasonable effort or expenditure. The defendants argued that the patient could have avoided death had he accepted a blood transfusion—a minimally invasive treatment with little risk.

The trial court granted the defendants’ motion for summary judgment. The court ruled that by rejecting a blood transfusion, the patient had failed to take advantage of objectively reasonable means to avoid the consequences of the defendants’ alleged negligent conduct. The court found that the blood transfusion was a minimally invasive procedure and that all three of the plaintiff’s expert witnesses agreed that it would likely have saved the patient’s life. Plaintiff appealed the trial court’s decision to the state’s court of appeals. The court of appeals affirmed the lower court’s ruling resulting in the final dismissal of this litigation.

The right to refuse medical treatment generally is a very complex area of the law. Due to conflicting legal precedents, the validity of the refusal of treatment depends on the patient’s situation. For example, if the patient is a minor, courts have generally ordered that blood transfusions be administered in life-threatening cases over the objections of parents who based their decision on religious grounds. State laws vary and are less clear for a minor in a less life-threatening situation. If the minor is a teenager, joint refusal of the patient and the parents would likely be valid.

Table 1: Depicts risk management strategies for providers managing patients who refuse medical treatment.

<table>
<thead>
<tr>
<th>Risk Management Strategies and Considerations for Patients Who拒绝 Medical Treatment?</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Educate the patient or their legal representative as much as possible about the treatment recommendations and the risks of refusing treatment</td>
</tr>
<tr>
<td>2. Attempt to discover the patient’s reasons for refusing care and discuss these with the patient to determine if there are ways to compromise so the patient can receive care that is in their best interests</td>
</tr>
<tr>
<td>3. With the patient’s permission, speak with family, legal representatives, or clergy to determine if that might help the patient reconsider their refusal of treatment</td>
</tr>
<tr>
<td>4. Consider a mental health referral if the patient has overwhelming anxieties about receiving care or shows psychiatric comorbidities and is willing to be evaluated</td>
</tr>
<tr>
<td>5. Document your efforts to educate the patient, the rationale for your recommended treatment, and the patient’s refusal of care</td>
</tr>
<tr>
<td>6. Have the patient sign a release that explains the risks inherent in refusing treatment and holds harmless the health care providers and facility from all liability arising out of the refusal of treatment</td>
</tr>
</tbody>
</table>

For these reasons, anesthesia and other healthcare professionals should seek the advice and assistance of legal counsel when caring for a patient who refuses medical treatment (Table 1). Also, hospitals and facilities need to develop a response in advance of a medical emergency because of these same complexities. If procedures are not already in place, it may be impossible to marshal the necessary resources within the time required by a medical emergency.

Brian J. Thomas, JD, is vice president of Risk Management at Preferred Physicians Medical (PPM), a medical professional liability company for anesthesia professionals, in Overland Park, KS.

The author has no conflicts of interest.

REFERENCES

*Grounds for summary judgment disposition vary pursuant to federal and state law. The grounds for the summary judgment motion being granted in this case were, “the opposing party has failed to state a claim on which relief can be granted,” and “there is no genuine issue as to any material fact, and the moving party is entitled to judgment as a matter of law.”

APSF NEWSLETTER June 2022 PAGE 65
Patient Safety and Quantitative Neuromuscular Transmission Monitoring in 2022

by Lawrence Caruso, MD, Samsun Lampotang, PhD, FSSH, FAIMBE, and Nikolaus Gravenstein, MD

Historically, intermediate-acting neuromuscular blockade has been accomplished by population-based dosing accompanied by clinical signs and/or subjective (qualitative) electrical stimulus-based twitch monitoring. Somewhat surprisingly, neuromuscular transmission (NMT) monitoring is still not a formally articulated basic anesthesia monitoring standard of care when an intermediate-acting neuromuscular blocker (NMB) is administered. Recently, the Anesthesi a Patient Safety Foundation (APSF) Committee on Technology advocated for NMT monitoring when an intermediate-acting muscle relaxant is used. The recommendation for NMT monitoring arises from accumulated experiences of residual neuromuscular blockade in postoperative patients, which is not a rare phenomenon. Such patients are subjected to the postoperative physiologic and psychological risks associated with chemically induced weakness. The psychological risk is obvious, whereas the physiologic ones can be obvious or subtle, but include hypoxemia, respiratory distress, need for supplemental oxygen, and longer recovery room stay. Residual neuromuscular blockade is most prevalent when a patient is assessed as being “clinically strong” before or after neuromuscular blockade reversal by using only clinical indicators (e.g., adequate tidal volume, grip strength, and/or five-second head lift). The practice of using only clinical monitoring for neuromuscular blockade and assessment of recovery persists despite ample documentation that residual neuromuscular blockade happens in approximately one in five patients on postanesthesia care unit arrival. Residual neuromuscular blockade is defined as when the ratio of the fourth to the first twitch height/excursion (T4/T1) is < 0.9 after intermediate-acting muscle relaxant administration.

With the growing ubiquity of nerve stimulators, there has been a steady move toward titration of NMBs against a motor response to an electrical stimulus. The stimulus is applied more commonly over the ulnar nerve to enable stimulation and assessment of a hypothenar or levator palpaberi response. Actually, monitoring the motor response to an electrical stimulus is a significant step forward over only dosing and reversing NMBs based on elapsed time, clinical response, and patient weight. Moving from clinical monitoring to train-of-four (TOF) NMT monitoring represents the initial next step in advancing the sophistication of NMT monitoring. TOF monitoring has been extensively studied; thus, we know that with no twitch response, there is nearly 100% neuromuscular receptor blockade (NMBR), with 1 twitch 90% NMBR, 2 twitches 80% NMBR, 3 twitches 75% NMBR, and still 0–75% NMBR with 4 twitches.

To obtain a more nuanced assessment, the medical professional assesses the T4/T1 ratio. The target ratio is at least 0.9 for typical adequate clinical reversal. Although the T4/T1 ratio can be assessed by visual inspection, palpation, or electronically, it is well described that visual and tactile assessment of the T4/T1 ratio is remarkably imprecise and unable to reliably discriminate between a ratio of 0.4 and >0.9. This is of clinical significance and explains the advocacy for implementing quantitative T4/T1 NMT monitoring (QNMT). In QNMT, the device reports a twitch count and then an objective T4/T1 ratio once there are at least 4 twitches. This allows objective verification that a ratio of at least 0.9 has been reestablished after spontaneous or pharmacologically reversed recovery. As a small aside, it is noteworthy that a baseline T4/T1 ratio is actually greater than 1. This is because the release of acetylcholine into the neuromuscular junction is not completely cleared between the TOF twitches; therefore, there is some potentiation. If a QNMT monitoring device is not available, then achieving sustained 5-s tetanus at 100 Hz approximates a T4/T1 ratio of roughly 0.9. Conversely, using 50-Hz tetanus is inadequate to assess adequate recovery/reversal, and it may be no better than using qualitative TOF.

Over the last 6 years, a new molecule, sugammadex, has become available to reverse neuromuscular blockade. Sugammadex encapsulates several of the intermediate-action NMBs (i.e., rocuronium and vecuronium). Unlike neostigmine, which creates a competitive antagonism by increasing acetylcholine in the neuromuscular junction, sugammadex does not have a ceiling effect. Despite the rapid and largely reliable pharmacodynamics of sugammadex, NMB still plays an important role to verify that the target T4/T1 ratio is >0.9 or that a sustained tetanus at 100 Hz has been achieved after sugammadex administration, as advised in the package insert. Skipping this step unnecessarily puts our patients in harm’s way. As one of our mentors used to say, the operating room is no place for optimism.

In fall of 2022, the APSF has included a QNMT module in the Technology Education Initiative to help provide clinicians with a better understanding and mental model for NMT monitoring and QNMT monitoring. NMB dosing, redosing, pharmacodynamics, interaction of volatile anesthetics with neuromuscular blockade, and reversal of neuromuscular blockade.

Lawrence Caruso, MD, is associate professor of anesthesiology and physician director of Quality, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL.

Samsun Lampotang, PhD, FSSH, FAIMBE holds the JS Gravenstein Professorship of Anesthesiology and is director, CSSALT and Innovations Director Office of Medical Education at the University of Florida College of Medicine, Gainesville, FL, USA.

Nikolaus Gravenstein, MD, is the Jerome H. Modell, MD, Professor of Anesthesiology and Professor of Neurosurgery and Periodontology, University of Florida College of Medicine, Gainesville, FL, USA.

The authors have no conflicts of interest.

Funding: Supported by the Jerome H. Modell, MD, Endowed Professorship (N.G.) and the Joachim S. Gravenstein Endowed Professorship (S.L.).

REFERENCES


Perioperative Considerations of Cannabis Use on Anesthesia Administration

by Dylan Irvine, BScH, Tricia Meyer, PharmD, MS, John Williams, MD, and Jeffrey Huang, MD

INTRODUCTION
As of 2018, an estimated 9.5% of the United States adult population were cannabis users.1 This percentage has likely continued to increase with the use of both recreational and medicinal cannabis in the United States. The use of medical cannabis is currently legal in 37 states, and recreational cannabis use is legal in 18 states, although cannabis use remains illegal federally. With the increasing prevalence of cannabis use among adults, it is important that anesthesia professionals recognize the potential cardiopulmonary, gastrointestinal, and central nervous system effects of cannabis use when providing perioperative care to those patients who consume cannabis.2

PHARMACOLOGICAL CONSIDERATIONS
The cannabis plant contains more than 500 compounds including cannabinoids, terpenoids, and flavonoids.3 The main cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the major psychoactive component responsible for the properties of sedation, analgesia, and euphoria. Cannabis refers to all products derived from this plant and marijuana refers to the parts of the plant (dried leaves, flowers, stems, and seeds) that contain substantial amounts of THC.4

The strength of cannabis is measured by the concentration of THC. The amount of THC in marijuana has been increasing, which may contribute to the increase in emergency room visits.5 The THC potency in confiscated marijuana samples from the Drug Enforcement Agency has increased from 3% in 1980 to 12% in 2012.6 The primary reason for the increase in THC strength is a more potent form of cannabis called sinsemilla. Sinsemilla is the female cannabis plant that has not been pollinated and now constitutes the major proportion of seized products.3,5 Additionally, more marijuana extracts and resins are being produced that contain 3–5 times more THC than the plant itself.3,5

The mechanism of action of the cannabinoids is binding and acting as a partial agonist on two types of G-coupled cannabinoid receptors, called cannabinoid receptor type 1 (CB1) and type 2 (CB2).6,7 The CB1 receptors are found, in the largest concentrations, in the brain and nervous system tissue, and less in the liver, adipose tissue, and vascular endothelium.6,7 The CB2 receptors are found predominantly in immune cells such as macrophages and mast cells.6,7 Activation of CB1 inhibits the release of several neurotransmitters including acetylcholine, L-glutamate, gamma-aminobutyric acid (GABA), norepinephrine, dopamine, and serotonin.6,7

Individuals typically intake marijuana through inhalation (smoking or vaporization) or ingestion of an edible product. The pharmacokinetics can be variable depending on the method of administration.6,7 THC is quickly transferred from the lungs to the bloodstream during smoking, and the onset of psychoactive effects occurs rapidly, within seconds to minutes. The psychoactive effects of THC from inhalation reach a maximum in 15 to 30 minutes and begin to taper off at 2–3 hours. However, the duration of action may be up to four hours. These effects mirror plasma THC concentrations.6,8 A small amount of inhaled THC, approximately 2 to 3 mg, may produce effects in a naïve user.6 Pulmonary bioavailability varies from 10 to 35 percent of an inhaled dose and is determined by the depth of inhalation along with the length of time of inhalation and breath-holding.7,8 Smoking is the most common route of intake, however; vaporization is on the increase.8,9 Similar psychoactive effects are experienced through vaporization although it may reduce exposure to by-products of combustion.7,9 However, possibly harmful and carcinogenic aerosols may be present in flavored cannabis vaporing products.10 Orally ingested cannabis has a later onset of action ranging from 60–120 minutes. Cannabis has low bioavailability because of degradation in gastric acid and first-pass metabolism in the liver.7 The inexperienced user may encounter psychotropic effects with 5 to 20 mg of ingested THC.8 Orally ingested cannabis reaches its peak effect at approximately 120 minutes and can last up to 4 to 6 hours. The elimination half-life of THC is difficult to measure and is slow, with times ranging from 25 to 36 hours. The slow-release occurs from lipid storage areas and enterohepatic circulation. The elimination half-life increases in regular cannabis users.7

THC has high lipophilicity and distributes to highly perfused tissues. It is also highly protein-bound (95 to 99 percent) mainly to lipoproteins and has a volume of distribution of 2.5 to 3.0 L/kg.7

Information regarding drug interactions with cannabis is limited as is with many naturally occurring compounds due to the complexity of the plant, variability in the THC content of available products, and lack of studies resulting from difficulty in studying a Schedule I drug. Some information is available through the prescribing information of cannabinoid-derived pharmaceutical medications.6

THC is mainly metabolized in the liver through the P450 complex as are many anesthetic drugs, and, therefore, there is a potential for pharmacokinetic drug interactions through either the inhibition or induction of these enzymes (Table 1).5,7,10 The few cannabis and cannabidiol metabolite drug interactions reported in the literature include increased effects of clobazam, warfarin, and hexobarbital, and a decreased effect of theophylline.12-15 There can also be additive pharmacodynamic effects with other agents having similar physiologic properties such as sedation with central nervous system depressant drugs, including benzodiazepines, opioids, and volatile agents.5,7

Table 1: Pharmacokinetic Drug Interactions With THC and Their Consequences6,7,11-15

<table>
<thead>
<tr>
<th>Interaction Type</th>
<th>Example Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased effects</td>
<td>Clobazam, warfarin, hexobarbital.</td>
</tr>
<tr>
<td>Decreased effects</td>
<td>Theophylline.</td>
</tr>
<tr>
<td>Additive pharmacodynamic effects</td>
<td>Other agents having similar physiologic properties such as sedation with CNS depressant drugs, including benzodiazepines, opioids, and volatile agents.</td>
</tr>
</tbody>
</table>

See “Cannabis and Anesthesia,” Next Page
Cannabis and Anesthesia

From “Cannabis and Anesthesia,” Preceding Page

**PREOPERATIVE CONSIDERATIONS**

There are some important preoperative considerations for patients that are cannabis users. First, it is important to take a good medical history, including the history of cannabis use (Table 2). The anesthesia professional should consider the composition of the products used, a history of adverse effects, the dose consumed, the effects caused by missed doses, and the time since last exposure. Understanding these factors is important in order to assess the risks of cardiovascular and respiratory problems, the potential for withdrawal symptoms (Table 3a), the effects of THC administration on delayed gastric emptying, and the risks associated with anesthesia administration during cannabis intoxication.6

The use of cannabis preoperatively may lead to significant safety issues for the patient and health care providers. Preoperatively, it is essential to assess for the signs and symptoms of acute cannabis intoxication, as acute intoxication poses the largest risk to anesthesia administration.6,17 Patients with symptoms of acute cannabis intoxication (Table 3b) are more likely to emerge from anesthesia violently. Among cannabis users who have a history of angina, it is important to inquire about angina-free functional capacity during cannabis use.8 In patients with an elevated risk of coronary artery disease, there is an increased risk of myocardial infarction in the first hour following the use of cannabis, and thus elective surgeries should be delayed by at least one hour following cannabis use in these patients. Preoperative cardiac function tests and cardiology consultation may be required. Cannabis has the potential to inhibit P450 enzymes.6 The patients on anticoagulation and antiplatelet medications should be evaluated for coagulation function. Preoperative lab tests may include PT, INR, and platelet function tests.

**INTRAOPERATIVE CONSIDERATIONS**

The current literature is lacking clinical guidance regarding intraoperative anesthesia management in cannabis users. Some research suggests that patients who regularly use cannabis may require larger induction and maintenance doses of anesthesia intraoperatively. Among some patients undergoing sedation for endoscopy procedures, there may be an association between cannabis use and higher intraoperative dose requirements of propofol to achieve adequate sedation, but these claims have not yet been supported by well-designed studies. A recent retrospective study assessing the impact of preoperative cannabis use in patients undergoing open reduction and internal fixation of tibia fractures specifically provided some evidence to suggest minimal effect of preoperative cannabis use on anesthetic dosing intraoperatively. Among the study cohort of 118 patients, of which more than 25% reported cannabis use prior to surgery, there was no significant difference in total propofol, dexmedetomidine, etomidate, ketamine, desflurane, midazolam, and fentanyl doses administered between those who used cannabis prior to surgery and those who did not (patients were classified as cannabis users if they self-reported any cannabis products use in the month prior to surgery, and nonusers if they did not use any cannabis products the month before surgery). The only agent for which there was a significant difference observed between these two groups was sevoflurane, where the average total volume of sevoflurane administered intraoperatively was significantly higher among the group who used cannabis (37.4 ml vs 25 ml, p=0.023). This study suggests that preoperative use of cannabis may lead to increased tolerance to sevoflurane, although the study has some notable limitations including its retrospective study design, and small sample size. Thus, future research is needed to verify these findings.

Anesthesia professionals should take extra caution when using intraoperative sympathomimetics and beta-blockers among those using cannabis due to potential inhibition of CYP-450. Furthermore, patients must be carefully monitored intraoperatively for signs of hemodynamic instability and signs of myocardial infarction or stroke. Anesthesia professionals should be prepared to manage airway hyperactivity intraoperatively if the patients do not have a secure airway due to potential airway irritation caused by preoperative cannabis use.

<table>
<thead>
<tr>
<th>Table 2: Perioperative Considerations of Preoperative Cannabis Use on Anesthesia Administration and Postoperative Pain Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PreOperative Considerations</strong></td>
</tr>
<tr>
<td>Assess for signs of cannabis intoxication.</td>
</tr>
<tr>
<td>Obtain comprehensive history of product composition, history of adverse effects, dose consumed, the effects caused by missed doses, and the time since last exposure.</td>
</tr>
<tr>
<td>Obtain history of angina and increased risk of coronary artery disease.</td>
</tr>
<tr>
<td>Evaluate for coagulation dysfunction (e.g., PTT, INR, and platelet function tests).</td>
</tr>
<tr>
<td>Consider delaying elective surgeries following acute patient consumption of cannabis</td>
</tr>
<tr>
<td><strong>PostOperative Considerations</strong></td>
</tr>
<tr>
<td>More likely to report higher postoperative pain scores and increased analgesic requirements.</td>
</tr>
<tr>
<td>Monitor for signs of cannabis withdrawal.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3a: Cannabis Withdrawal Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anger</td>
</tr>
<tr>
<td>Irritability</td>
</tr>
<tr>
<td>Nervousness/Anxiety</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
<tr>
<td>Anxiety</td>
</tr>
<tr>
<td>Paranoia</td>
</tr>
<tr>
<td>Psychosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3b: Symptoms of acute cannabis intoxication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased anxiety</td>
</tr>
<tr>
<td>Paranoia</td>
</tr>
<tr>
<td>Psychosis</td>
</tr>
</tbody>
</table>

See “Cannabis and Anesthesia,” Next Page
Perioperative Considerations in Those Patients Who Consume Cannabis

From “Cannabis and Anesthesia,” Preceding Page

POSTOPERATIVE CONSIDERATIONS

Postoperatively, there are two main considerations for patients who are cannabis users: challenges in the management of postoperative pain, and managing withdrawal symptoms.7 8 Several studies have demonstrated that cannabis users are more likely to report higher pain scores, poorer sleep, and require a greater quantity of analgesic medications in the immediate postoperative period than nonusers.19 20 Therefore, multimodal analgesia and appropriate opioid dosing should be considered for these patients.8 It is also important to monitor cannabis users for signs and symptoms of withdrawal postoperatively (Table 3a).23 Withdrawal onset can take place within 1–2 days of the last cannabis use and last 1–2 weeks; thus, health care providers should monitor for signs of cannabis withdrawal in postoperative patients until cannabis use is resumed.5 Postoperative shivering, hypothermia, and increased platelet aggregation have also been documented among cannabis users.4 Prophylactic hypothermia and shivering is thought to be mediated by CB1 receptor activation and, thus, are not suspected to be due to withdrawal symptoms.23 Increased platelet aggregation is likely due to CB1 and CB2 receptors existing on platelet membranes by a high dose of THC.24

CONCLUSION

The increasing use of cannabis, both medically and recreationally, has resulted in new and important perioperative considerations for anesthesia professionals (Table 2). Having a better understanding of the possible effects of cannabis use perioperatively can help providers mitigate perioperative risk and better manage postoperative pain in patients receiving anesthetic anesthesia.

Dylan Irvine is a second-year medical student at Nova Southeastern University College of Osteopathic Medicine, Davie, FL.

Tricia A. Meyer is an adjunct professor in anesthesiology, Texas A&M College of Medicine, Temple, TX.

John Williams, MD, is a CA1, PGY-2, anesthesiology resident at BSW Memorial Hospital in Temple, TX.

Jeffrey Huang, MD, is a senior member of Anesthesiology, Health Outcomes and Behavior at Moffitt Cancer Center, and a professor of oncological science at the University of South Florida, FL.

Tricia Meyer is a speaker for Accdia. The other authors have no conflicts of interest.

REFERENCES

3. NIDA. Myth or Fact? “Marijuana is stronger these days” [https://archives.drugabuse.gov/blog/post/myth-or-fact-marijuana-stronger-these-days]. Accessed April 1, 2022.
For more information about how your organization can support the APSF mission and participate in the 2022 Corporate Advisory Council, go to: apsf.org or contact Sara Moser at: moser@apsf.org.

2022 Corporate Advisory Council Members (current as of February 1, 2022)

Platinum ($50,000)

- BD (bd.com)
- Fresenius Kabi (fresenius-kabi.us)
- GE Healthcare (gehealthcare.com)
- Masimo (masimo.com)

Gold ($30,000)

- BAUDEX BBAUDEX BIO
- Bink Device Company
- Edwards Lifesciences
- ICUMED
- ICU Medical
- Medtronic
- Medtronic Lifesciences
- Merck
- Nihon Kohden
- America
- Preferred Physicians Medical Risk Retention Group
- Vyara Medical

Silver ($10,000)

- Dräger
- Heron Therapeutics
- Pall Corporation
- Senzime

Special recognition and thank you to Medtronic for their support and funding of the APSF/Medtronic Patient Safety Research Grant ($150,000); and Merck for their educational grant.

For more information about how your organization can support the APSF mission and participate in the 2022 Corporate Advisory Council, go to: apsf.org or contact Sara Moser at: moser@apsf.org.

Community Donors (includes Specialty Organizations, Anesthesiology Groups, ASA State Component Societies, and Individuals)

Specialty Organizations

- $5,000 to $14,999
- $2,000 to $4,999
- $750 to $1,999
- $2,000 to $4,999
- $750 to $1,999
- $200 to $749
- $2,000 to $4,999
- $750 to $1,999
- $5,000 to $14,999

American Academy of Anesthesiology Assistants

- Minnesota Society of Anesthesiologists
- Indiana Society of Anesthesiologists

Gold ($30,000)

- ASA State Education Programs Donation
- North American Partners in Anesthesia
- Intersurgical, Inc.
- American Society of Anesthesiologists (asahq.org)

Silver ($10,000)

- Community Donors (includes Specialty Organizations, Anesthesiology Groups, ASA State Component Societies, and Individuals)

Note: Donations are always welcome. Donate online (https://www.apsf.org/donate/) or mail to APSF, P.O. Box 6668, Rochester, MN 55903. (Donor list current as of April 1, 2021–March 31, 2022.)
The Institute for Safe Medication Practices (ISMP) convened on November 10–11, 2021, as a virtual national summit on Perioperative Medication Safety. The intent of the summit was to leverage the current understanding of the causes of medication errors and known successful mitigations to develop additional preventative strategies to further reduce patient harm in the perioperative clinical setting. The summit was attended by approximately 80 stakeholders from various backgrounds including anesthesia professionals, perioperative nurses, pharmacists, industry representatives from both drug manufacturing and equipment related to medication safety, and ISMP staff. The Anesthesia Patient Safety Foundation (APSF) served as a sponsor of the conference along with a number of companies interested in this topic.

The conference began with an overview of summit objectives followed by five presentations on the Current State of Perioperative Medication Safety, Barriers to Safety with a focus of Reporting and Culture, the survey results of the ISMP Medication Safety Self-Assessment for Perioperative Settings, and the survey results of the Levels of Agreement from summit attendees prior to the summit.1,2 The main areas of focus of the conference consisted of medication labeling and packaging in the perioperative setting and the adoption of safety technology in the perioperative space. There were several areas of consensus. For example, 97% of summit respondents agreed or strongly agreed that smart infusion pumps should be used for continuous medication infusions, and 81% agreed that barcode scanning for medication administration should be used in the PACU and postoperative care areas.2 There were also areas of less agreement such as the use of barcode scanning technology in intraoperative and intraprocedural locations to verify medications prior to administration (63%) and the use of smart pumps in all perioperative settings, including intraoperatively, for intravenous hydrating solutions (68%).2

It was recognized by summit attendees that agreement in principle on the use of medication error reduction technologies does not consistently translate to utilization within procedural areas. A self-assessment survey of 98 hospitals and 33 ambulatory centers was conducted by ISMP to evaluate technology availability and utilization.1 Responses demonstrated that 93% of hospitals and only 35% of ambulatory centers had access to smart infusion pumps.1 In addition, 87% of hospitals and only 12% of ambulatory centers indicated that barcode scanning was available for medication administration.1 While smart pumps and barcode scanning were available in many facilities, this did not consistently translate to implementation. Barriers to adoption of technologies were explored such as cost and provider preferences and opportunities to advance safety were discussed including expanding technology availability and education.

There were several presentations in each area of focus, including case studies, followed by breakout group discussions on topics of Labeling, Barcode Medication Administration (BCMA), and Smart infusion pump technology (Table 1) with 4–5 groups and 12–15 participants per group. The breakout groups were led by a facilitator with specific questions to generate discussion (Table 1). Each breakout group reported back key points to the main audience.

### Table 1. Sample Breakout Questions

#### Breakout Session #1: Labeling

1. Should handwritten labels ever be used for routine medication labeling?
2. Should printing labels be considered best practice?
3. Are you handwriting your own label now? If so, why?
4. How do we get practitioners to recognize the risk associated with nonstandard labeling practices and adopt safe labeling expectations?

#### Breakout Session #2: Barcode Scanning

1. Are there general organizational expectations for barcode scanning use for medication administration in your facility (outside of the intraoperative setting) for all medication and fluids?
2. Is there currently an expectation for barcode scanning use during medication administration in your intraoperative settings?
3. What workflow concerns do you have about the use of Barcode Medication Administration (BCMA) intraoperatively for medication use?

#### Breakout Session #3: Smart Infusion Pump Integration and Optimization

1. Are there challenges with patient transfer from the operating room to another level of care when there are different infusion devices?
2. Do you believe there are benefits of smart infusion pump integration with the Electronic Health Record?
3. What type of training and competency assessments are provided related to smart infusion pump use? For nurses? For anesthesia providers? For nonanesthesia sedation providers?

Discussion points to highlight include the preference of labeling syringes in concentration per mL by anesthesia professionals to reduce the potential of a mathematical error while administering medications in the perioperative environment, the lack of support/resources for BCMA especially in ambulatory surgery centers and procedural locations, and the lack of smart pump standardization within different locations of the hospital.

Important takeaway points from the conference consisted of recognizing rank order of error reduction strategies in terms of leverage (low to high), level of effectiveness (least to most) and ease of implementation. Preferences among stakeholders attending the meeting for drug labeling consisted of concentration per mL versus the current way of total drug per total volume. The labeling discussions addressed issues related to manufacturer labeling of vials, ampules, infusions, and prefilled syringes. Advantages of BCMA technology such as interfacing with the Electronic Health Record (EHR) were discussed along with a number of companies interested in this topic.
APSF Sponsors ISMP Summit on Medication Safety

From “ISMP Summit,” Preceding Page

The conference concluded with discussion on consensus building on topics including improving safety culture and medication error reporting in the perioperative area, utilizing innovation to address unmet needs and challenges, and to develop consensus guidelines around perioperative medication safety.

At the time of publication of this article, draft guidelines are under review by conference participants. Once this input is received, ISMP will post the full draft guidelines for public comment. After the public comments have been reviewed internally, ISMP will then publish the final guidelines. APSF members were participants in the conference and will be included in the reviews. APSF members will utilize internal organizational discussion to provide recommendations consistent with APSF current expert opinion. Final ISMP guidelines release is expected in late 2022.

REFERENCES


The authors have no conflicts of interest.

Elizabeth Rebello, Rph, MD, CPPS, CMQ, FASA, is a professor in the Department of Anesthesiology and Perioperative Medicine at the University of Texas MD Anderson Cancer Center.

John Beard, MD, is chief medical officer of GE Healthcare Life Care Solutions.

The APSF now offers you the opportunity to learn about anesthesia patient safety on the go with the Anesthesia Patient Safety Podcast. The weekly APSF podcast is intended for anyone with an interest in perioperative patient safety. Tune in to learn more about recent APSF Newsletter articles with exclusive contributions from the authors and episodes focused on answering questions from our readers related to patient safety concerns, medical devices, and technology. In addition, special shows that highlight important COVID-19 information on airway management, ventilators, personal protective equipment, drug information, and elective surgery recommendations are available. The mission of the APSF includes being a leading voice for anesthesia patient safety around the world. You can find additional information in the show notes that accompany each episode at APSF.org. If you have suggestions for future episodes, please email us at podcast@APSF.org. You can also find the Anesthesia Patient Safety Podcast on Apple Podcasts or Spotify or anywhere that you listen to podcasts. Visit us at APSF.org/podcast and at @APSForg on Twitter, Facebook, and Instagram.
LETTER TO THE EDITOR:

The Impact of Health Disparities in Patient Safety

by Lilibeth Fermin, MD, MBA; Luis E. Tollinche, MD, FASA; Judith L. P. Handley, MD; and Amy Lu, MD, MPH

The recent COVID-19 pandemic has highlighted the health disadvantage of the most vulnerable members of the society.1 The literature about health disparities in the perioperative setting and their impact in patient safety is growing. Different authorities, like the executive branch of government and physicians’ organizations, have raised concern about the negative environment fostered by health disparities in patient experience and outcomes.2,4

The latest National Healthcare Quality and Disparities Report shows that health care disparities are present in the US population, mainly among the poor and uninsured. The report stated, “Blacks and American Indians and Alaska Natives received lower quality care than Whites for 40% of quality measures.” The patient safety measures in which Black adults received worse care than Whites during the 2016–2018 period included postoperative physiologic and metabolic derangements per 1,000 elective surgical hospital discharges, sepsis diagnoses per 1,000 elective-surgery admissions, postoperative pulmonary embolism per 1,000 surgical hospital discharges, and postoperative acute kidney injury requiring dialysis per 1,000 elective surgical hospital discharges.5

While we cannot change the socioeconomic conditions of our individual patients, as members of the anesthesia care team we are charged with delivering equal treatment to our patients.

Health disparities place the vulnerable population at risk during health care interactions. Delayed or inadequate diagnosis, inappropriate coordination of care, fragmented communication, and lack of a safety culture that embraces patient individuality and promotes family engagement fosters an unsafe environment.6

Global equity in health delivery should be our goal, and we want to provide possible solutions to the problem in the perioperative environment. Some researchers believe that unequal health treatment can be attributed to the hospital in which the patient receives care while others favor individual-provider factors as the source of disparities.7,8 The American Society of Anesthesiologists, the American Association of Nurse Anesthesiology, the American Academy of Anesthesiologist Assistants, and the American Board of Anesthesiology have published statements acknowledging racial and ethnic disparities in anesthesia care and promoting health equity.9,10 Health care providers do not exist in isolation. Clinicians are part of a community and some of their behaviors are products of cultural imprinting. As members of the wider population, providers can unconsciously display the same implicit bias reflected in members of their community.11,12 Bias, implicit bias, and stereotyping are some of the attitudes that need to be mitigated and abolished in order to prevent disparities in health care. Implicit bias is an unconscious, unjustified, negative attitude or feeling towards an individual of a certain group, while explicit bias is a conscious prejudicial evaluation.13,14

The latest National Healthcare Quality and Disparities Report advocates for a more diverse workforce in order to promote better access, improve communication, and meet the underserved community needs.5 Researchers have seen higher participation in preventive screenings with physician-patient gender concordance, and enhanced patient experience with patient-physician racial concordance.9,8 Diversity is also needed in the anesthesiology field, where 74% of active anesthesiologists are male, and 65% of

Table 1: Suggestions to Mitigate Health Disparities

<table>
<thead>
<tr>
<th>Clinician Level</th>
<th>System Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recognize personal bias</td>
<td>Create a culture of equity</td>
</tr>
<tr>
<td>Encourage intrinsic motivation to change behavior</td>
<td>Provide health equity training</td>
</tr>
<tr>
<td>Participate in continuing education about health disparities</td>
<td>Encourage health equity initiatives in research, and clinical field</td>
</tr>
<tr>
<td>Engage in community outreach initiatives</td>
<td>Provide financial incentives for measures that are linked to health equity</td>
</tr>
<tr>
<td>Advocate for health equity at a legislative level</td>
<td>Promote governance that supports health equity and patient safety</td>
</tr>
</tbody>
</table>

See “Health Disparities,” Next Page
Health Disparities in the Perioperative Space

From “Health Disparities,” Preceding Page

Luis E. Tollinche, MD, FASA, is chair of anesthesiology, MetroHealth Medical Center, Cleveland, OH.

Judith L. P. Handley, MD, is a clinical associate professor, Department of Anesthesiology and Perioperative Medicine, Medical College of Georgia/Augusta University.

Amy Lu, MD, MPH, is a clinical associate professor, vice chair Quality, Safety and Improvement, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford School of Medicine.

Luis E. Tollinche, MD, served as a paid consultant and in an advisory role for Merck & Co. Pharmaceutical Company and is a grant recipient through the Merck Investigator Studies Program to fund a clinical trial at MSKCC (NCT03808077). Lilibeth Fermín, MD, Judith Handley, MD, and Amy Lu, MD, have no conflicts of interest.

REFERENCES

LETTER TO THE EDITOR:
Sustainable Health Care Must Be the Next Patient Safety Movement
by Jonathon P. McBride, MD, MS, and Matthew J. Meyer, MD

The harm done by health-care-related pollution is equivalent to the medical errors that sparked the patient safety movement. Anesthetic gas are one of the largest and most modifiable sources of health care sector greenhouse gas (GHG) emissions. Anesthesia professionals have the opportunity to lead the health care sector’s response to pollution and climate change.

Last summer, an older woman living in the usually mild climate of British Columbia suffered dyspnea following an extraordinary heatwave—her physician diagnosed her with “climate change.” While she is the first known to receive the diagnosis of climate change, she is not the first patient whose health has suffered because of climate change. She will not be the last.

Climate change is already affecting the health of our patients. Yet, the health care sector is just beginning to understand the impact of environmental health on population health, and to evaluate its large contribution to global emissions and climate-related morbidity.

IMPACT OF ANESTHESIOLOGY ON OUR ENVIRONMENT

The modern health care sector is responsible for an estimated 8.5% of United States GHG emissions; pollution that harms the very people the health care sector cares for (Figure 1). It is essential for the entire health care sector to evaluate and reduce its impact on the environment. Responding to climate change, and its downstream population health impact, is an opportunity for anesthesia professionals to lead on patient safety once again.

Pharmaceutical-related emissions account for approximately 20% of health care sector GHG emissions, more than food service, construction, or transportation. Volatile anesthetics and nitrous oxide can trap hundreds to thousands of times more energy than carbon dioxide. One study found anesthetic gases could be the source of over 50% of the GHG footprint of the entire operating room (OR) suite.

Desflurane and nitrous oxide have the highest impact on climate change due to their energy trapping ability and the concentration at which they are used clinically; sevoflurane is the least harmful, but still multiple times worse than the potent GHG methane. In a study comparing the GHG emissions per Minimum Alveolar Concentration (MAC)-hour of anesthesia, propofol is orders of magnitude less impactful on the climate than any volatile anesthetic.

Adding to the harm of nitrous oxide, a recent study found intrahospital delivery of nitrous oxide to be dangerously inefficient with upwards of 70% of procured nitrous oxide being lost via leakage. The loss of nitrous oxide from hospital storage to OR utilization is a potential patient and occupational safety issue.

Making modifications to the delivery of anesthesia care (Figure 2) provides an opportunity to reduce our profession’s environmental impact and provide higher value patient care. For example, a multidisciplinary OR green team including anesthesia professionals at the University of Wisconsin Health educated the anesthesiology department on anesthetic gas waste, low-flow anesthesia, and differential GHG emissions of volatile anesthetics. Within three years they reduced their GHG emissions 64% per case while saving $25,000 per month. Furthermore, even if a health system institutes sustainable anesthesia practices like low fresh gas flows (<1L per minute), reusable instruments, and the elimination of desflurane and nitrous oxide, there is still an opportunity for the attentive, individual anesthesia professional to make a notable impact.

See “Sustainable Health Care,” Next Page
Anesthesia Professionals Can Reduce Environmental Harm and Improve Patient Safety

From “Sustainable Health Care,” Preceding Page

HOW TO GET INVOLVED?

As global priorities shift and patients and organizations demand a more sustainable economy, health care will have to change. The current practice of medicine is unsustainable. In an unprecedented call to action, over 200 medical journals, including the New England Journal of Medicine, and The Lancet, published an editorial calling for emergency action to reduce greenhouse gas emissions and limit future harm.1,3

Climate change and environmental pollution are global, existential problems that require coordinated and collective action that can provoke anxiety and concern.1,6 There are many great organizations leading health care’s response to the climate crisis: Healthcare without Harm, Practice Green Health, and The Medical Society Consortium on Climate and Health. These three organizations lead the sustainable health movement in the United States. In addition, Medical Students for a Sustainable Future is a student-led organization for climate and health advocacy.

To be leaders in sustainable health care, anesthesiology professionals must reduce the harm of their own practice and begin to advocate for more sustainable health systems. Health care institutions have both great responsibility and great ability. The health care sector is responsible for one-sixth of the entire US GDP, creating sustainable health care systems can catalyze change throughout the entire economy. Anesthesia professionals have the opportunity to reduce the environmental harm of our practice and again take a leading role in this next patient safety movement.

Jonathon P. McBride, MD, MS, is an incoming anesthesiology resident at the University of Michigan.

Matthew J. Meyer, MD, is an assistant professor of anesthesiology at the University of Virginia.

Matthew J. Meyer, MD, has consulted for Dialectica and received speaking fees from Takeda Pharmaceutical for a scientific forum on sustainability. Dr. Meyer has intellectual property related to perioperative efficiency and sustainability. Matthew J. Meyer, MD, is on the steering-committee of Virginia Clinicians for Climate Action. Jonathon P. McBride, MD, is a member of White Coats for Planetary Health and Medical Students for a Sustainable Future.

REFERENCES


Get Social With Us!

The APSF is eager to connect with patient safety enthusiasts across the internet on our social media platforms. Over the past year, we have made a concerted effort to grow our audience and identify the best content for our community. We’ve seen increases in followers and engagement by several thousand percent, and we hope to see that trajectory continue into 2022. Please follow us on Facebook at https://www.facebook.com/APSForf/ and on Twitter at https://twitter.com/APSForf. Also, connect with us on LinkedIn at https://www.linkedin.com/company/anesthesia-patient-safety-foundation-apsf/. We want to hear from you, so please tag us to share your patient-safety-related work, including your academic articles and presentations. We’ll share those highlights with our community. If you are interested in joining our efforts to amplify the reach of APSF across the internet by becoming an Ambassador, please reach out via email to Marjorie Stiegler, MD, our Director of Digital Strategy and Social Media at stiegler@apsf.org. Emily Methangkool, MD, the APSF Ambassador Program Director at methangkool@apsf.org, or Amy Pearson, Social Media Manager at pearson@apsf.org. We look forward to seeing you online!
What do all of these individuals have in common?

Join us!  https://www.apsf.org/donate/legacy-society/

An abiding belief in safeguarding the future of anesthesiology. Established in 2019, the APSF Legacy Society honors those who make a gift to the foundation through their estates, wills, or trusts, thus ensuring that patient safety research and education will continue on behalf of the profession about which we are so deeply passionate.

APSF recognizes and thanks these inaugural members who have generously supported APSF through an estate or legacy gift.

For more information about planned giving, please contact Sara Moser, APSF Director of Development at: moser@apsf.org.